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Abstract
Implications of NEDD9 on AURKA activity: a biomarker for sensitization and therapeutic 
target in solid tumors.
Ryan Joseph Ice
The spread of cancer, known as metastasis, is the major cause of relapse and inability 
to cure disease. Invasion of cancer cells into neighboring tissue and to distant sites 
allows cancer cells to evade therapeutic agents, due to the low therapeutic penetration 
of certain tissues such as the central nervous system, and eliminates the feasibility of 
resection; which is why the study of pro-metastatic proteins is of great urgency, one 
such protein is NEDD9. NEDD9 is overexpressed in various tumor types and is 
correlated with poor prognosis due to a more invasive and metastatic phenotype.
NEDD9 serves as a scaffolding protein at the intersection between cell proliferation, 
through activation of mitotic Aurora A kinase (AURKA), and invasion, through regulation 
of Src kinase and matrix metalloproteinase 14, MMP14, activity. The overall aim of my 
work is to determine the role of NEDD9 in tumorigenesis and its implications on AURKA 
activity in tumor cells. AURKA is up regulated in the majority of human cancers, but not 
in normal cells making it a promising target for therapeutic interventions. There are 
several highly specific AURKA small molecule inhibitors in clinical trials to treat cancer. 
Nevertheless, it was unknown how NEDD9 binding to AURKA affects inhibitor efficacy,
AURKA degradation, proliferation, and migration of tumor cells. My current studies have
answered some of these critical questions allowing for further improvements of AURKA 
based therapeutics leading to prolonging patient survival. Study one demonstrates that 
NEDD9 protects AURKA from degradation and limits the successful application of 
AURKA inhibitors leading to greater metastasis. Additionally, we established that the 
AURKA inhibitor MLN8237 (Alisertib), currently in Phase III clinical trials to treat 
advanced lymphomas, has the ability to eliminate breast cancer metastases. Study two 
establishes NEDD9 as a necessary scaffolding protein for invasion of breast cancer 
cells by regulating the activity of a key extracellular matrix (ECM) degrading enzymes
such as MMP14 and its inhibitor, TIMP2. Study three illustrates the ability of NEDD9 
overexpression to increase MMP dependent mammary gland development and 
potentially promote tumorigenesis in a transgenic animal model. Furthermore, study 
three details the development of a conditional NEDD9 transgenic mouse strain that can
be utilized for various studies. Finally, study four details the method and feasibility of 
utilizing patient derived xenograft models for future AURKA inhibitor testing in the 
treatment and prevention of metastatic breast cancer. Taken together, this thesis 
illustrates the importance and clinical applications of studying the NEDD9-AURKA 
signaling hub in treating tumor metastasis.    
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Literature Review
1. AURKA: Cell Cycle Regulator and Oncogene
1.1 AURKA activation and domain structure
Aurora Kinase A, also known as AURKA, is a mitotic serine/threonine kinase activated 
by an autophosphorylation at amino acid, threonine 288, near the activation loop of the catalytic 
domain. Upon phosphorylating threonine 288, the activity of AURKA dramatically increases 
(Walter 2000, Ohashi 2006). The AURKA inactivation is regulated by protein phosphatase type 
2a (PP2a) which dephosphorylates and inactivates AURKA (Katayama 2001). Additionally, 
AURKA activity is curtailed through proteasome mediated degradation, which will be covered in 
later chapters. AURKA belongs to the Aurora family of proteins, consisting of three known 
members: Aurora A, Aurora B and C. All Aurora kinases possess a variable amino terminal 
domain (N) along with a conserved catalytic domain (Cat) (Fig.1).
Fig. 1 Structure of AURKA. Illustrating the regulatory domain and catalytic 
domain (http://atlasgeneticsoncology.org)
Despite the structural similarity, the role of AURKA is distinct from Aurora B and C. The N-
terminal domain (aa 1-128) allows AURKA to localize to centrosomes (MTOC-microtubule 
organizing centers) and interact with microtubules during mitosis (Giet 2001). The structure of 
AURKA is such that the N-terminal domain inhibits the catalytic domain when AURKA is not 
bound to AURKA activating proteins (Zhang 2007). Binding partners and activators, such as 
NEDD9 and TPX2, allow for the release of autoinhibition, resulting in autophosphorylation of 
threonine 288 (Pugacheva 2007, Kufer 2002). Once AURKA is activated, phosphorylation of 
serine 51, known as the A-Box, is achieved via autophosphorylation protecting AURKA from 
degradation (Littlepage 2002). Finally, active AURKA is targeted then to the centrosome through 
microtubule binding were it can function as a mitotic kinase.
1.2 The role of AURKA in the regulation of cell cycle and aneuploidy
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Entry into mitosis, one of the phases of cell cycle, is controlled through the activation of 
Cdk1 by forming a complex with CyclinB1 (Gavet 2010). AURKA regulates the formation of this 
complex through phosphorylation and activation of cdc25b phosphatase, which removes an 
inhibitory phosphorylation from Cdk1 (Horn 2007). Accumulation of AURKA at the centrosome is 
required for centrosome maturation and segregation (Wang 2010). After initiation of mitosis and 
nuclear envelop break down AURKA is targeted from the centrosome to mitotic spindle through 
its association with microtubule binding protein TPX2 (Kufer 2002). Microtubule bound AURKA 
continues to phosphorylate multiple targets leading to their loading on to the mitotic spindle thus 
orchestrating spindle assembly. By regulating both CyclinB1/Cdk1 complex activity and mitotic
spindle loading, AURKA regulates both early G2/M phase transition and mitosis itself. Absence 
of AURKA in normal cells results in G2/M arrest or if cells already passed G2/M, the formation 
of a monopolar spindle, inability to separate DNA and lethality (Glover 1995). Similar 
phenotypes are also present in knockout embryos of AURKA knockout mice being non-viable 
even at day 3.5 due to formation of blastocyst consisting of multinucleated cells leading to 
chromosome disarray, and retarded growth (Sasai 2008).
1.3 The function of AURKA in tumorigenesis
Overexpression of AURKA, which is common in most cancers, leads to amplification of 
centrosomes and multipolar spindle formation resulting in aneuploidy, due to the miss 
segregation of chromosomes during mitosis (Tatsuka, 1998). Under normal circumstances 
aneuploidy will lead to apoptosis, controlled cell death; however, in the absence of necessary 
cell cycle checkpoints, such as p53, the cancer cell will continue to divide resulting in 
chromosome instability. Chromosome instability, a hallmark of many cancers, leads to an 
increase in mutation rate and a more aggressive phenotype (Meraldi, 2002). To exacerbate the 
phenotype, AURKA has been shown to phosphorylate p53 at serine 215, which inhibits p53 
DNA binding and transactivation activity (Liu 2004). Other studies show that AURKA is able to 
phosphorylate p53 at serine 315 which targets p53 for degradation by Mdm2 via proteolysis 
(Katayama 2004). Overexpression of AURKA will result in a decrease in p53, promoting 
chromosome instability. Since p53 is a major cell cycle and DNA damage checkpoint the result 
of p53 inhibition is increased resistance to radiotherapy and chemotherapeutic drugs, such as 
cisplatin and gamma-radiation, which rely on DNA damage checkpoints to induce apoptosis. 
1.4 Expression of AURKA in human cancers
AURKA was first discovered to be a part of an amplified portion of chromosome 20q13 
during a colon cancer screen. The levels of both AURKA protein and mRNA are increased in 
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more than 50% of primary colon cancers and are increased in breast and other solid tumors 
(Bischoff 1998). Independently, AURKA is seen to be amplified in 12% of primary human breast 
tumors (Zhou, 1998). AURKA is an oncogene and when overexpressed AURKA is able to 
transform rodent fibroblasts and mouse 3T3 cells (Bischoff 1998, Zhou 1998) stating the 
importance of AURKA regulation for normal cell growth. While gene amplification is one 
mechanism for increased AURKA mRNA and protein found in some breast, colon, prostate, 
neuroblastoma, and cervical cancer tumors increased levels of mRNA are also found 
independent of amplification suggesting that there are multiple pathways leading to increased 
levels of AURKA (Li 2003, Gritsko 2003, Reichardt 2003). In a survey of pancreatic cancers cell 
lines all nine tested and 22 of 38 pancreatic cancer patient tissues had from twice to ten times 
the amount of AURKA protein when compared to matching normal tissues (Li 2003). In fact 
when tested via immunohistochemical staining, elevated levels of AURKA protein are found in 
94% of invasive ductal breast adenocarcinomas; while AURKA is barely detectable in benign 
breast lesions (Tanaka 1999).
1.5 The impact of AURKA expression in drug resistance and cancer treatment
An important point for breast cancer treatment is the presence of estrogen and progesterone 
receptors in the tumor, as these receptors can be utilized as sites for targeted therapy. When 
breast cancer tumors are assessed for AURKA levels they positively correlated with both 
advanced stage and loss of estrogen and progesterone receptors. In other words, the more 
aggressive and harder to treat tumors had more AURKA present, thus indicating AURKA as a 
target for inhibitor therapy in tumors resistant to endocrine therapy (Miyoshi 2001). In other 
studies, high AURKA levels are detected in premalignant state tumors which were later resistant
to hormone therapy in a carcinogen induced rat tumor model, suggesting once again that 
AURKA is a predictive marker for endocrine resistant phenotypes (Goepfert 2002).
The ability to create resistance to standard therapy is a hallmark of AURKA. High levels 
of AURKA not only allow tumor cells to accrue chromosomal abnormalities thereby increasing 
mutation rates, but also allow tumor cells to bypass key mitotic spindle checkpoints, thus 
making the cells resistant to the chemotherapeutic drugs such as paclitaxel (Anand 2003).
However, the ubiquitousness of AURKA overexpression does allow for combinational therapies 
to be attempted and give hope for patients by utilizing AURKA inhibitors. Additionally, the ability 
of AURKA to repress the DNA damage checkpoint ability of p53 makes AURKA an important 
protein for combinational therapies, due to many chemotherapeutics needing p53 activity to 
induce apoptosis. More specific to breast cancer is the finding that familial breast cancers 
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containing BRCA2 mutations have increased levels of AURKA, pointing to a site for targeted 
therapy for this very aggressive form of breast cancer (Bodvarsdottir 2007).
1.6 Animal models of AURKA over-expression and cancer 
Proving AURKA to be an oncogene, AURKA overexpression is able to induce tumor 
formation by 20 months in genetic animal models where AURKA expression is driven by mouse 
mammary tumor virus (MMTV) promoter. Even before tumors formed, cells present with 
elevated Akt levels, the target of rapamycin, and high nucleated cyclin D1 levels resulting in 
increased rates of proliferation. Not surprisingly, the cells also presented with extreme 
chromosome abnormalities, and yet did not undergo apoptosis (Wang 2006). Additionally in the 
mouse mammary model system, when AURKA is overexpressed proliferation rates increase 
dramatically as does the levels of p53, due to chromosome defects. Surprisingly, the presence 
of high p53 does not induce apoptosis in these tumor cells. In the background of p53 
inactivation, AURKA overexpression in the mammary fat pad is able to induce tumorigenesis at 
a faster rate, suggesting p53 pathway activation is overcome through selective adaption (Zhang 
2004).
1.7 The role of AURKA in invasion and metastasis
     While early detection and targeted therapies have increased the survivability of many 
cancers; once invasion from the primary site has occurred survivability of disease greatly 
decreases. Early reports show AURKA activity stimulates collagen I induced invasion, migration, 
and anchorage independent growth, via RalA phosphorylation. RalA is a member of the Ras 
family of proteins and is responsible for the formation of filopodia protrusions and vesicle 
trafficking (Wu 2005). AURKA has also been implicated in migration and invasion through its 
ability to phosphorylate Akt at serine 473, which leads to greater migration rates (Guan 2007).
AURKA phosphorylates and  activates the actin severing factor, cofilin, directly regulating actin 
dynamics involved in migration and invasion potential of cancer cells (Wang 2010); therefore, 
AURKA targeted  therapies could prove efficient against invasive and metastatic cancers.
2. AURKA Inhibitors: A promising therapeutic target
2.1 Rational and Development of AURKA inhibitors
Kinases contain a conserved ATP binding site critical for enzymatic function and share a 
similar biochemical mechanism of action. They are considered as a first line for designing 
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targeted therapies. By blocking the ATP binding site of a kinase, utilizing molecules that 
compete with ATP for binding, one can easily inhibit the enzymatic activity of the kinase. Out of 
the three Aurora family members, only AURKA and AURKB regulate the cell cycle and could be
targeted to inhibit division; however, only AURKA expression and activity had been shown to 
correlate with survival of cancer patients. High AURKA protein levels are a negative indicator of 
survival (Nadler 2008). Inhibition of AURKA more efficiently induces mitotic deficiencies and
apoptosis or senescence than inhibition of AURKB (Warner 2006). Additionally, since AURKA 
can repress the DNA damage checkpoint through inactivation of p53 inhibition of AURKA will be 
beneficial for many combinational therapies which rely on p53 activity to induce apoptosis. 
The first attempt in designing effective AURKA inhibitors occurred once the crystal 
structure of AURKA was defined down to 1.9Å (Nowakowski, 2002). The next proof of concept 
experiments, utilizing computer modeling and inhibitor docking in silico followed by in vitro 
inhibitor kinase assays, proved AURKA to be a druggable target (Mahadevan 2003).
2.2 The efficacy of AURKA inhibitors in vitro and clinical trials
The development of VX-680, tozasertib, a pan Aurora inhibitor, with a Ki of AURKA 
0.6nM, AURKB 18nM, and AURKC 4.6nM, demonstrated the first successful clinical application 
of Aurora inhibitors. VX-680 shows efficacy in xenograft experiments for leukemia, colon and 
pancreatic tumors (Harrington 2004). Next, it was found in primary human and mouse prostate 
cancer cells that VX-680 is able to induce apoptosis; additionally, VX-680 is able to increase 
apoptosis by two fold when combined with doxorubicin, a chemotherapeutic (Lee 2006).Another 
inhibitor of the Aurora family, ZM447439, showed the ability to inhibit chromosome 
condensation and microtubule spindle formation; however due to the higher efficacy in targeting 
AURKB (Ki= 0.36nM) than AURKA (Ki= 100nM) the inhibitor was unable to induce apoptosis 
while increasing aneuploidy (Gadea 2005). Showing promise as a drug target, further modeling 
and drug design was performed to target AURKA, introducing the use of tricyclic scaffolds 
(Warner 2006, Heron 2006). Building upon this work, a second generation of AURKA inhibitors 
was developed: PHA-680632, with an IC50 of 27nM for AURKA and 135nM for AURKB, shows 
promise by inducing growth arrest in various tumor line xenografts and a transgenic breast 
cancer line. However, the inhibitor was unable to eliminate disease by decreasing tumor burden 
(Soncini 2006).
By investigating the mechanism of growth arrest and apoptosis induced by the various 
inhibitors one can understand which protein to target, AURKA or AURKB, and what mitotic 
checkpoints are needed to induce apoptosis. Looking at multiple cell lines, both with and without 
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p53 and p21, researchers were able to discover that VX-680 induces two types of apoptosis. In 
cells containing wild type p53 and p21 cells undergo apoptosis upon entering mitosis, due to 
DNA duplication accompanied by a lack of segregation of chromosomes. In cells lacking p53 
and/or p21, cells undergo endoreduplication, genome duplication without cytokinesis, to the 
extent of being non-viable (Gizatullin 2006). The ability of AURKA inhibitor, PHA-680632, to 
induce apoptosis in p53 null cells is further shown in HCT116 colon cancer xenograft 
experiments, illustrating the additive effect of AURKA inhibitors when combined with 
radiotherapy. The additive effect of AURKA inhibitors is due in part to p53 deficient cells being 
selected for when DNA damage agents are utilized (Tao 2007). VX-680 also shows much 
greater cytotoxicity than ZM447439, an AURKB specific inhibitor, suggesting that induction of 
apoptosis is through AURKA (Tyler 2007). Studies also show that AURKA inhibition in multiple 
myeloma cells leads to apoptosis via aneuploidy, with neither IL-6 nor activated Ras pro-survival 
pathways protecting the cells from apoptosis (Shi 2007). Further investigation of AURKA 
inhibition induced apoptosis, via the AURKA specific inhibitor MLN8054, reveals that the 
mechanism of action is not necessarily decreased mitosis but deleterious aneuploidy (Hoar 
2007). The next generation variant of MLN8054, MLN8237 (alisertib), is currently in Phase IV 
clinical trials for treatment of myeloid lymphoma and melanoma,
2.3 The impact of AURKA binding partners on the efficacy of AURKA Inhibitors
Since AURKA activation is induced through binding partner associations and 
autophosphorylation, it would stand to reason that AURKA interactors would influence the 
efficacy of inhibitions. Examples of AURKA activators are TPX2, AJUBA, and NEDD9 (Eyers 
2003, Hirota 2003, Pugacheva 2007). TPX2, targeting protein for Xklp2, is a mitotic protein 
present at the start of the G1/S transition and is degraded at the end of cytokinesis. TPX2 binds 
the carboxyl terminus of AURKA in a phosphate-independent manner allowing for a local 
conformational change in the activation domain, resulting in both AURKA autophosphorylation 
and protection from phosphotases, therefore locking AURKA in its active state (Kufer 2002, 
Eyers 2003, Bayliss 2003). More explicitly, through binding TPX2, the glycine rich loop, proximal 
to the adenosine triphosphate binding site in the amino acid terminus of AURKA, swings via a 
hinge region to protect AURKA from dephosphorylation (Eyers 2005).
Utilizing the known dynamics of TPX2 activation of AURKA, computer modeling of 
AURKA, both with and without activator binding, establishes that the hydrophobic pocket 
adjacent to the adenosine triphosphate (ATP) binding site, which many inhibitors use to lodge in 
the active site, is closed upon TPX2 binding (Anderson 2007). Computer modeling experiments 
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were confirmed by the co-crystal structure of bound AURKA/TPX2/VX-680 down to a resolution 
of 2.3 Å. The structure shows the binding of VX-680 to AURKA/TPX2 in a completely novel 
manner, via binding of the glycine rich hinge region in the hinge region AURKA (Zhao 2008).
These findings support the claim that AURKA binding partners influence heavily AURKA
inhibitor binding profile, pharmacodynamics, and are areas for further investigation. 
Combination therapies utilizing AURKA inhibitors and Src inhibitors show efficacy and 
synergistic effects. Both Src and AURKA interact with NEDD9, serving as a point of crosstalk 
between the two pathways, pointing to the importance of AURKA interactors as a source for 
combination therapy design (Ratushny 2012).
3. NEDD9: The oncogenic scaffolding protein
3.1 Structure, binding partners, and post-translatable modifications of NEDD9
The Crk-Associated Substrate (Cas) family of proteins contains four members: 
BCAR1/p130Cas, EfS/Sin1, NEDD9/HEF1/Cas-L, and CASS4/HEPL. Cas proteins function as 
scaffolding proteins, serving as a platform for proteins to bind therefore increasing the likelihood 
of a reaction taking place. Additionally, the Cas family of proteins serves as a mediators of 
signaling through post-translational modifications, such as phosphorylation, leading to a change 
in protein binding affinities and conformational changes. Between NEDD9, Neural cell precursor 
expressed developmentally down-regulated 9, and p130Cas, p130Cas is ubiquitously 
expressed in all tissues and is found localized to focal adhesions within cells; while, NEDD9 is 
tissue specific and is found throughout the cell. Both proteins contain four domains: 1) a Src 
homology 3 domain (SH3) which is able to bind proline rich regions of neighboring proteins; 2) a
substrate domain, containing multiple tyrosine residues, which upon phosphorylation serve a 
docking sites for other proteins; 3) a serine rich region, and 4) a carboxyl terminal domain which 
contains the focal adhesion targeting region (Fig.2).
Figure 2. Diagram of NEDD9 domains
Both, NEDD9 and p130Cas are able to be phosphorylated by various kinases, such as Src, 
focal adhesion kinase (FAK), and Abl (Law 1996). To further complicate the parsing of roles 
8 
 
between p130Cas and NEDD9, the two proteins heterodimerize via a Helix Loop Helix (HLH) 
motif in the carboxyl terminal domain of the two proteins (Law 1999).
One way to tease out the role of NEDD9 apart from p130Cas is to look at lymphocytes 
which naturally lack p130Cas. In T lymphocytes, NEDD9 is phosphorylated in response to 
activation of integrin ?1 on the cell surface via direct binding of FAK and NEDD9 (Minegishi 
1996, Van Seventer 2001). In addition to activating T cells, NEDD9 plays a role in the B cell 
activation cascade. Upon ligands binding B cell antigen receptors (BCR) on the surface of B 
cells, NEDD9 is phosphorylated as a part of a signaling cascade ending in the rearrangement of 
the actin cytoskeleton promoting division and migration (Manié 1997). NEDD9 also plays a role 
in myeloid cell activation by serving as a critical hub for phosphorylation and binding. Upon 
myeloid immunoreceptor tyrosine-based activation motif (ITAM) binding on the cell surface, Cbl, 
Crkl, and NEDD9 are tyrosine phosphorylated forming a complex leading to Rap1 activation, a 
small GTPase, resulting in the loosening of cell adherence junctions (Kyono 1998).
Functioning as a critical scaffolding protein allows NEDD9 to influence a multitude of 
signaling pathways. As a result of FAK phosphorylation, in the presence of integrin ?1, 
phosphorylated NEDD9 levels, increasing activation of such pathways as: Jun N-terminal 
protein kinase (JNK), transforming growth factor-beta (TGF??? hypoxia-inducible factors 1 & 2 
(HIF), and suppression E-cadherin junctions. In the case of the JNK pathway, phosphorylated 
NEDD9 binds to active JNK leading to a further increase in NEDD9 levels in a positive feedback 
loop, demonstrating the ability of NEDD9 to regulate JNK dependent apoptosis (Law 2000).
NEDD9 influences the TGF??pathway through sequestering Smad6 and Smad7, negative 
regulators of the TGF??pathway (Inamoto 2007). Additionally, NEDD9 functions as a hypoxia 
inducible factor, since inactivation of von Hippel-Lindau (VHL) tumor suppressor activates HIF 
leading to phosphorylation of NEDD9 (Xu 2010). NEDD9 is also phosphorylated in response to 
cells being stimulated by epithelial growth factor (EGF) and heregulin (HRG) leading to MAPK 
activation (Nagashima 2008).
As with all phosphorylated events, a phosphatase is needed to negatively regulate the 
binding cascade; similar to the mechanism to inactivate AURKA, NEDD9 is dephosphorylation
by PP2A thereby enabling the cell to reset the binding cascade of NEDD9 (Bradbury 2012).
3.2 NEDD9 expression in Human Cancers
To understand the importance of a protein in cancer one can look at how ubiquitously 
the protein is found to be up or down regulated in various cancer types. Increased levels of an 
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individual protein can be caused through a multitude of mechanisms such as: increased 
transcription, decreased degradation, targeting by microRNA, and, in the case of cancer, 
increasing the number of copies in the genome. 
NEDD9 is found to be upregulated in Philadelphia chromosome positive leukemia, 
where NEDD9 functions as a scaffold between oncogenic Bcr/Abl and downstream effectors 
Crkl and Cbl (de Jong 1997). By comparing multiple melanoma cell lines, NEDD9 is shown to 
be the only gene consistently amplified resulting in overexpression of the protein, leading to 
increased invasion and migration of melanocytoes (Kim 2006). Corroborating this finding, in 
patient samples (n=19) the NEDD9 locus 6p24 is seen by fluorescence in situ hybridization 
(FISH) to be amplified in 57% of melanoma patients (Moore 2008). Additionally, in matching 
normal and lung adenocarcinomas samples NEDD9 tumor expression and protein levels are 
significantly increased, correlating with tumor stage and grade, leading to poor prognosis 
(Chang 2012, Kondo 2012). Similar findings are seen in matching pancreatic ductal 
adenocarcinoma samples, increasing amounts of NEDD9 correlate with poor prognosis and 
higher grade tumors (Xue 2013). In glioblastoma patient samples, microRNA-145 (miR-145) is 
downregulated resulting in an increase in NEDD9 expression correlating to higher grade and 
decreased patient survival (Speranza 2012). Taking a closer look at lung adenocarcinomas 
NEDD9 correlated with hallmarks of epithelial to mesenchymal transition (EMT), such as 
fibronectin, and abnormal E-cadherin and ?-catenin expression along with an increase in N-
cadherin (Miao 2013). The importance of NEDD9 in carcinogenesis was further demonstrated,
in an oncogene-driven genetic mouse model of mammary tumors (MMTV-PyVmT). The NEDD9 
knockout in this model led to a significant delay in cancer initiation, decrease in cancer growth,
overall tumor burden, and metastasis. The cancer cells from tumors produced in these animals 
have dramatic decreases in FAK, Src, and Akt activity, along with deficiencies in invasion and 
migration (Izumchenko 2009).
3.3 The role of NEDD9 in Invasion & Migration
NEDD9 functions in lymphoblastic cells as a scaffolding protein, allowing for crosstalk 
between signaling pathways in response to integrin ?1 and T cell receptor (TCR) stimulation 
(Kamiguchi 1999), and leading to lymphocytic migration. Binding to extracellular matrixes and
TCR stimuli results in phosphorylation of NEDD9, changing the binding characteristics of the 
protein, and thereby inducing migration and invasion (Ohashi 1999). NEDD9 is also important 
for the formation of neurite protrusions of neurons (Bargon 2005). In embryonic development, 
NEDD9 is essential for neuronal crest cell migration (Aquino 2009). Focal adhesion kinase 
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(FAK) serves as the link between surface signaling and NEDD9 phosphorylation. When FAK 
binds activated integrins, FAK phosphorylates itself and NEDD9, inducing migration (Van 
Seventer 2001). NEDD9 is critical for migration of glioblastoma cells in response to platelet 
derived growth factor (PDGF) via NEDD9 localization to focal adhesions. NEDD9 plays such an 
important part of the focal adhesion kinase (FAK) cascade that the increase in invasion and 
migration due to overexpressed FAK is abrogated when NEDD9 expression is impeded 
(Natarajan 2006).
Cells have two classes of movement, mesenchymal and ameboid. Mesenchymal 
movement is characterized by well-developed adhesions and matrix degradation through the 
formation of ventral actin based protrusions known as invadopodia, allowing the cell to pierce 
through basal membranes and other heavily cross-linked extracellular matrixes. Ameboid 
movement is characterized by few adhesion points and a matrix contraction (without 
degradation) based movement via actin-myosin cytoskeleton dynamics through lightly or non-
cross-linked extracellular environment. Mesenchymal movement is driven by activation of the 
GTPase Rac, while ameboid movement is driven by the GTPase Rho. NEDD9 regulates the 
switch between the two types of movement by activating Rac and inhibiting Rho through 
downstream effectors (Sanz-Moreno 2008). NEDD9 forms a complex with Rac and DOCK6 
thereby activating Rac. Activated Rac inhibits Rho via WAVE2. TGF?, known activator of EMT, 
induces mesenchymal movement via upregulation of NEDD9 (Giampieri 2009). Another 
mesenchymal promoting factor is vascular endothelial growth factor (VEGF). VEGF induces the 
formation of invadopodia in a NEDD9 dependent manner (Lucas 2010).
In addition to functioning directly as a switch between mesenchymal and ameboid 
movement, NEDD9 is a known epithelial to mesenchymal transition (EMT) inducer. NEDD9 has 
the ability, through Src, to disrupt the localization of E-cadherin to the cell surface and promote 
lysosomal degradation of E-cadherin (Tikhmyanova 2011, Kong 2011). E-cadherin is necessary 
for epithelial cell-cell junctions. In the absence of proper E-cadherin localization the cell can, 
transform into a more invasive mesenchymal-like phenotype resulting in potentially greater 
metastasis. Silencing of NEDD9 in low E-cadherin expressing cells results in reduced FAK and 
Src phosphorylation and restores epithelial morphology (Sima 2013). Other prominent EMT 
transducer proteins, such as Twist, also upregulate NEDD9 expression along with Rac1 and 
DOCK3 in order to promote mesenchymal type movement of the cell (Yang 2012).
3.4 The role of NEDD9 in regulation of the Cell Cycle and AURKA.
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While NEDD9 is present during all phases of the cell cycle it is upregulated significantly 
during the G2/M transition and early stages of mitosis. During mitosis NEDD9 localizes to the 
mitotic spindle poles (centrosomes) and mitotic spindle (Law 1998). At the centrosomes,
NEDD9 binds to and changes the conformation of AURKA, allowing for AURKA to undergo 
autophosphorylation and activation. Overexpression of NEDD9 leads to an increase in 
centrosome number and multipolar spindles, resulting in an aneuploidy phenotype similar to 
AURKA overexpression (Pugacheva 2005). Interestingly, the amoeboid movement promoting 
protein, RhoA is necessary for cell rounding during mitosis and RhoA inactivation is necessary 
for cytokinesis, the division of cytoplasm. NEDD9 functions to activate RhoA, via the mitotic 
guanine exchange factor (GEF) Ect2; therefore, overexpression of NEDD9 could lead to 
cytokinetic defects and polyploidy (Dadke 2006).
NEDD9 also functions to regulate the cell cycle by regulating primary cilia. Primary cilia 
are found on the apical surface of epithelial cells. The cilium is comprised of microtubules with 
the lone centriole of the cell at the base, because of this there is only one cilium per cell. In 
preparation for entering the cell cycle, primary cilia must be disassembled. NEDD9, in 
conjunction with AURKA, sits at the base of the cilia and promotes microtubule deacetylation 
and depolymerization via HDAC6 phosphorylation leading to cilia disassembly and initiation of 
mitosis (Pugacheva 2007).
Cells lacking NEDD9 have a similar phenotype as cells with AURKA aberrations. While 
in murine spontaneous tumor models eliminating NEDD9 results in decreased invasion and later 
onset, the tumors that do develop have delayed mitosis and are hyperaggressive in part 
because of increased mutation rates due to mitotic defects. Increased mutation rates during 
tumorigenesis, similar to other paradigms such as antibiotic resistance, result in a delay in 
growth during the selection phase; however, once populations of cells have been selected the 
cells are more aggressive and resistant to treatment (Singh 2010).
3.5 Transcript regulation of NEDD9 expression in normal and tumor cells
Many signaling cascades involve increased transcription of NEDD9 leading to increases 
in invasion, migration, proliferation, and induction of EMT. The EMT promoting factor, 
TGF??induces a sixteen fold increase in NEDD9 mRNA levels, resulting in an increase in Src 
and FAK activity (Zheng 2002). Increased levels of NEDD9 lead to an increase in TGF?
signaling through a positive feedback loop (Bruna 2012). Another EMT factor that can induce 
NEDD9 expression is FoxC1, a member of the Fox family of transcription factors. The ability of 
FoxC1 to induce migration and invasion is in part due to the upregulation of NEDD9 (Xia 2013).
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The established EMT inducing Wnt pathway is another cascade resulting in increases in 
NEDD9 transcription. Members of the canonical Wnt cascade such as: Wnt, ?-catenin, and Dvl2 
are all able to increase NEDD9 transcription; conversely, ?-catenin knockdown results in 
decreased levels of NEDD9 (Li 2011). Upon treatment of cells with Wnt inhibitors NEDD9 levels 
drop, reducing invasion and migration of tumor cells independent of Src or FAK activation (Iida 
2012).
A second instance where NEDD9 expression is transcriptionaly induced is under hypoxic 
conditions. Cells experience hypoxia when the level of oxygen in the surrounding tissue does 
not meet the requirements of the cell. Tumors often experience hypoxia when growth outpaces 
angiogenesis and under inflammatory conditions. Hypoxia is known to induce EMT and increase 
migration and invasion of various tumors. Cyclooxygenase-2 (Cox-2) is activated under 
inflammatory conditions. Prostaglandin E(2), a downstream component of the Cox-2 pathway, 
induces NEDD9 expression thereby increasing cellular proliferation and migration (Xia 2010).
Hypoxia inducible factor-1? (HIF-1?) is a hypoxia induced transcription factor. NEDD9 is a 
direct transcriptional target of HIF-1?, leading to increased migration when HIF-1??is induced. 
Upon NEDD9 depletion HIF-1? is no longer able to induce migration, showing the critical nature 
of NEDD9 in this cascade. Interestingly, NEDD9 also enhances the transcriptional activity of 
HIF-1???resulting in a positive feedback loop (Kim 2010). Yet another mechanism of induced 
NEDD9 expression in response to hypoxia is via the activation on ribosomal protein S6 kinase 
(S6K), which is a part of the mammalian target of rapamycin (mTOR) pathway. The mTOR/S6K 
pathway responds to metabolism disturbances, such as limited nutrients. Upon activation, S6K 
leads to transcriptional increases in hypoxia response genes, one of which is NEDD9 (Ismail 
2012).
4. Regulation of NEDD9 and AURKA through degradation
It is important for the homeostasis of a cell to control the amount of each protein within it.
Coordinated degradation of cell cycle regulated proteins is an example of how cells can 
accomplish the intricate balance of protein levels. It is necessary for mitotic proteins to be kept 
at low levels by degradation when the cell is not undergoing mitosis and to inhibit degradation 
during mitosis. In order to accomplish this task, the cell utilizes recognition subunits coupled to 
ubiquitin ligases. Each recognition subunit targets a specific set of proteins, thereby 
coordinating protein degradation depending on the cells requirements. Many proteins are 
degraded via the ubiquitin pathway, in which proteins are post translationally modified with 
ubiquitin molecules which signal to the cell that the proteins are to be degraded and trafficked to 
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the proteasome. Proteins that are to be degraded are first bound by recognition subunits of 
ubiquitin ligases. Once bound by the full ubiquitin ligase complex, ubiquitin ligases along with 
recognition subunits, the protein is labeled with ubiquitin molecules and shuttled to the 
proteasome for degradation. By utilizing the same ubiquitin ligase and recognition subunits, cell 
cycle proteins are able to be degraded in a coordinated manner, signaling the end of mitosis. 
In order to accomplish this coordinated destruction the cell employs the E3 ubiquitin 
ligase APC, anaphase promoting complex, and its recognition subunit cdh1. Cdh1 binds to cell 
cycle proteins at the end of mitosis and signals for APC to conjugate ubiquitin to the protein, 
thereby targeting the mitotic proteins to the proteasome for degradation. By degrading cell cycle 
proteins APC plays an important role in stopping proliferation. In a survey of 108 invasive breast 
cancers, APC was found to be decreased while mitotic index, histologic, and nuclear grade
increased (Park 2005).
Both AURKA and NEDD9, the focus of this study, are degraded in a cdh1/APC 
dependent manner (Honda 2000). AURKA is targeted by cdh1 via the D-Box in the carboxy 
terminus and a unique A-Box in the variable amino terminus of the protein (Arlot-Bonnemains 
2001, Taguchi 2002). The A-box functions as the main site of cdh1 binding, while the D-box 
functions as a second site after A-Box ubiquitination; therefore, allowing AURKA degradation to 
be independently regulated from AURKB, which contains only a D-box motif (Castro 2002).
Multiple studies show that gene amplification does not account for the levels of accumulated 
AURKA in tumor cells; additional mechanism must be present to create such abundant AURKA 
detected in tissue and cell lines (Crane 2005, Klein 2005). Interestingly, phosphorylation of 
serine at amino acid position 51 in the A-box completely blocks cdh1 dependent degradation of 
AURKA, suggesting that dephosphorylation plays a role in both AURKA inactivation and 
degradation (Littlepage 2002, Kitajima 2007). In order to exit the cell cycle cdh1/APC 
ubiquitinates AURKA, leading to mitotic exit and cytokinesis. Knockdown of cdh1, via siRNA,
leads to a similar phenotype as non-degradable AURKA mutants, failure of cytokinesis and 
aneuploidy (Floyd 2008).
Feedback loops also exist to keep NEDD9 levels in check during non-mitotic phases of 
the cell cycle. NEDD9 is targeted for destruction upon TGF??induction, which was discussed 
earlier as a promoter of NEDD9 transcription, via Smad3 interacting with the APC/cdh1
complex. By both being able to induce transcription and increase NEDD9 degradation, TGF? is 
able to keep NEDD9 transcription and protein increases transient (Li 2000, Nourry 2004). An 
additional mechanism to keep NEDD9 function in check is the ability of PP2A, a phosphatase 
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that targets NEDD9, to protect NEDD9 from destruction. The preference to degrade 
phosphorylated NEDD9 illustrates how APC/cdh1 functions to keep NEDD9 activity at bay
(Zheng 2006). Interestingly, the phosphorylation site that promotes APC/cdh1 binding is serine 
396 not serine 296; indicating AURKA dependent phosphorylation is not a signal for NEDD9 
destruction since serine 296 is the major target of AURKA phosphorylation (Hivert 2009). 
5. Genetic mouse models of human breast cancer 
While tissue culture systems are easy to use they are drastically oversimplified and 
artificial, due to the limited ability to reproduce the tumor microenvironment and the adaptation 
of the cells to grow on plastic. Genetic mouse models of human breast cancer provide a useful 
and informative alternative. There are multiple mammary specific promoters utilized in the field 
such as: ?????? ???????????????????????????????????????????????? ??????????????????????????
and keratin 14 (K14) (Borowsky 2011).  While the MMTV, WAP, and BLG promoters are 
expressed in luminal epithelial cells, the K14 promoter is expressed in the basal cells (Derksen
2006). 
Utilizing these promoters one can overexpress an oncogene, a dominant negative tumor 
suppressor, or conditionally knockout a tumor suppressor to create mammary specific 
tumorigenesis. When tumor suppressors such as p53 are mutated heterogenic tumors develop 
with long latency due to accumulation of mutations. Simultaneous p53 and E-cadherin 
inactivation results in a phenotype very similar to invasive lobular carcinoma (Alvarez 2006).
The most characterized mouse model system is MMTV-PyVmt, polyoma virus middle T 
antigen. PyVmT is used to mimic the over expression of Erbb2, which is found to be 
overexpressed in 25% human breast cancers (Lee 2010). PyVmT mimics the heterodimer 
Erbb2/Erbb3 in a dimerization and ligand-independent manner. Activation of Src, PP2A, and 
PI3K are found in both pathways (Dilworth 2002). Perhaps one of the major characteristics of 
this model system is that the tumors generated are very consistent. Tumorigenesis is 100% 
penetrant with tumors appearing at 20 weeks of age, with tumors initiated at 4 weeks of age. 
Mice often present from multiple foci tumors. Tumors also present with weak, though present, 
estrogen receptor signaling (Namba 2005).
Due to the early onset of tumorigenesis in the MMTV-PyVmT model, a good alternative 
is the MMTV-Her2 mouse model. Her2/Erbb2 heterodimerizes with other Her family members 
and activates the PI3K and MAP kinase pathways. Mice present with tumors between 8 to 12 
months when the wild type Her2 is used and 5 to 10 months when the activated mutant form of 
the protein, neu, is used. Both neu and Her2 models present with frequent pulmonary 
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metastasis (Muller 1998, Guy 1992). 37% of tumors in the wild type Her2 overexpressing mice 
have missense mutations of the p53 gene, suggesting the p53 plays an important role in Her2 
induced tumorigenesis (Li 1997).
6. Patient derived xenografts (PDX) as a promising new model for preclinical anti-
cancer drug testing 
Orthotopic human tumor xenografts contain distinct advantages over transgenic model 
systems since transgenic breast cancer in mice often does neither phenocopy human 
metastasis nor human breast cancer pathology. Through utilizing human tumor xenograft one 
can manipulate tissue culture cells in order to recapitulate genetic aberrations found in human 
tumor samples. Additionally, the inclusion of imaging reporters such as luciferase and RFP 
reduces the number of mice needed per study since euthanization is not necessary to measure 
tumor volume, burden, or metastasis (Jenkins 2005). Also, through the use of orthotopic human 
tumor xenografts, one is able to treat the same tumor with multiple treatments and different 
stages of disease. 
Until recently, most existing in vivo orthotopic models utilized for preclinical assays of 
anticancer drugs were based on a limited number of cell lines; which were previously isolated 
from human tumors and selected through culturing before being implanted into immunodeficient 
animals. Unfortunately, cell lines do not reflect the heterogeneity of human breast cancer 
resulting in a weak correlation between animal study results and clinical results. In the Study 4, 
we developed new preclinical models based on engraftment of patient-derived tumor samples 
that were directly transplanted into animals. In contrast with cell line-derived xenografts, patient-
tumor xenografts maintain their cell differentiation, morphology, architecture, and the molecular 
signatures of the original patient tumors (DeRose 2011). A higher correlation between drug 
response of patient-derived tumor xenografts and corresponding original tumors is expected 
allowing further development of more efficacious, individualized tumor therapies.
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Abstract
Aurora A kinase (AURKA) is overexpressed in 96% of human cancers and is considered an 
independent marker of poor prognosis. While the majority of tumors have elevated levels of 
AURKA protein, few have AURKA gene amplification, implying that posttranscriptional 
mechanisms regulating AURKA protein levels are significant. Here, we show that NEDD9, a 
known activator of AURKA, is directly involved in AURKA stability. Analysis of a comprehensive 
breast cancer tissue microarray revealed a tight correlation between the expression of both 
proteins, significantly corresponding with increased prognostic value. A decrease in AURKA, 
concomitant with increased ubiquitination and proteasome-dependent degradation, occurs due 
to depletion or knockout of NEDD9. Reexpression of wild-type NEDD9 was sufficient to rescue 
the observed phenomenon. Binding of NEDD9 to AURKA is critical for AURKA stabilization, as 
mutation of S296E was sufficient to disrupt binding and led to reduced AURKA protein levels. 
NEDD9 confers AURKA stability by limiting the binding of the cdh1–substrate recognition 
subunit of APC/C ubiquitin ligase to AURKA. Depletion of NEDD9 in tumor cells increases 
sensitivity to AURKA inhibitors. Combination therapy with NEDD9 short hairpin RNAs and 
AURKA inhibitors impairs tumor growth and distant metastasis in mice harboring xenografts of 
breast tumors. Collectively, our findings provide rationale for the use of AURKA inhibitors in 
treatment of metastatic tumors and predict the sensitivity of the patients to AURKA inhibitors 
based on NEDD9 expression.
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Introduction
The serine/threonine kinase, AURKA, is a proto-oncoprotein that is overexpressed in 
most cancers (1–3). High AURKA expression is strongly associated with decreased survival and 
is an independent prognostic marker (4). AURKA overexpression disrupts the spindle 
checkpoint activated by paclitaxel or nocodazole, inducing resistance to these compounds (5). 
Inhibition or depletion of AURKA protein may therefore improve the survival of patients resistant 
to paclitaxel (5). While 94% of the primary invasive mammary carcinomas have elevated 
AURKA protein levels (6), only 13.6% show AURKA gene amplification (1, 3). Thus, 
posttranscriptional mechanisms of AURKA stabilization are important in breast cancer. 
AURKA is polyubiquitinated by the anaphase-promoting complex/cyclosome (APC/C) 
complex and targeted for degradation by the proteasome (7). APC/C-dependent degradation of 
AURKA requires cdh1, which acts as a substrate recognition subunit for a number of mitotic 
proteins, including Plk1 and cyclin B. Overexpression of cdh1 reduces AURKA levels (8), 
whereas cdh1 knockdown or mutation of the AURKA cdh1–binding site results in elevated 
AURKA expression (7–9). AURKA is ubiquitinated through the recognition of a carboxyl-terminal 
D-box (destruction box) and an amino-terminal A-box, specific for the destruction of AURKA (10, 
11). Phosphorylation of AURKA on Ser51 in the A-box inhibits cdh1-APC/C–mediated 
ubiquitination and consequent AURKA degradation (9). 
Cancer cells express high levels of AURKA independently of a cell cycle, which 
suggests that there are additional mechanisms of AURKA stabilization. Recently, a number of 
proteins were documented to be involved in the regulation of AURKA stability either by direct 
deubiquitination of AURKA (12) or through interference with AURKA ubiquitination by APC/C 
(PUM2, TPX2, LIMK2; refs. 13–15.) 
NEDD9 is a member of metastatic gene signature identified in breast adenocarcinomas 
and melanomas (16–18). NEDD9 is a cytoplasmic docking protein of the CAS family. NEDD9 
regulates proliferation directly by binding to and activating AURKA (19). In nontransformed cells, 
activation of AURKA by NEDD9 in interphase is tightly controlled by a limited amount of NEDD9 
in cytoplasm. Overexpression of NEDD9 leads to the activation of AURKA resulting in 
centrosomal amplification and aberrant mitosis (19). NEDD9 undergoes ubiquitination and 
proteasomal degradation by APC/C. Like typical APC/C substrates, NEDD9 has D-box motifs 
and cdh1 binds to a D-box located within the carboxyl-terminal domain (20, 21). 
The strong link between increased AURKA expression and cancer progression has 
stimulated development of AURKA inhibitors for cancer therapy. PHA-680632 (22, 23), 
MLN8054, and MLN8237 (24, 25) are potent small-molecule inhibitors of AURKA activity. These 
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compounds have significant antitumor activity in various animal tumor models with favorable 
pharmacokinetics (23). However, clinical trials with MLN8054 as a single agent failed to show 
tumor growth inhibition (25, 26). In the present study, using human breast cell lines and 
xenografts, we have identified NEDD9 as a critical regulator of AURKA protein stability and 
sensitivity to AURKA inhibitors. Depletion of NEDD9 via short hairpin RNAs (shRNA) decreases 
AURKA protein, sensitizes tumor cells to AURKA inhibitors, and eliminates metastasis in 
xenograft models of breast cancer. Combination therapy using NEDD9 shRNAs and AURKA 
inhibitors might prove to be an effective treatment strategy for solid tumors with NEDD9 
overexpression. 
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Materials and Methods
Plasmids and reagents
shRNAs, siRNAs against human NEDD9, AURKA, and control expressed in pGIPZ or in 
doxycycline-inducible pTRIPZ vectors (Thermo Fisher Scientific). Lentiviral particles were 
prepared as previously described (26). Wild-type, Ser296Ala-A, S296/298-AA, Ser296Glu-E, 
and S296/298-EE cDNAs of murine NEDD9 were subcloned into pLUTZ lentiviral vector under 
doxycycline-inducible promoter. pcDNA3.1-myc-Ubiquitin and pcDNA3.1-HA-NEDD9 were used 
for u?????????????? ????????? ?????????? ??? ?????? ??? ????? ???? ????? ??? ????????? ??? ?? ??????
doxycyline. 
Cell lines and culture conditions
The cell lines MDA-MB-231, BT-549, BT-20, ZR-75-1, MCF7, and MDA-MB-231-luc-D3H2LN 
(MDA-MB-231LN) expressing luciferase (Caliper Life Sciences) were purchased and 
authenticated by American Type Culture Collection. After infection (or transfection) of shRNAs 
(or siRNAs), cells were selected for puromycin resistance and tested by Western blotting. 
Protein stability studies
Approximately 2 ×107 cells were plated; 12 hours later, fresh medium containing cycloheximide 
???? ??? ??? ????????? ???? ???????????? ?????? ???? ??? ??????? ??? ?????????? ?? ?? ??????????? ??????
were lysed in protein Triton-based cell lysis buffer (19) with ubiquitin aldehyde (1–?? ?????????
protease inhibitors (Sigma). 
Cell-cycle analysis by flow cytometry
The fluorescence-activated cell-sorting (FACS) analysis was done according to a previously 
published protocol (19). Cell-cycle distribution was analyzed by FACSCalibur equipped with Cell 
Quest software. 
Quantitative real-time PCR
Quantitative PCR (qPCR: ref. 27) was carried out in an ABI 7500 Real-Time PCR Cycler and 
analyzed using Applied Biosystems SDS software. 
Immunohistochemical analysis
High-density breast cancer tissue microarrays BR2082 (Supplementary Table S1) were 
collected with full donor consent. Immunohistochemical (IHC) procedures were done according 
to the manufacturer's recommendations (US Biomax Inc.) in duplicates. Manual scoring of 
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staining intensity [negative (0), weak (1+), moderate (2+), or strong (3+)], as well as location 
and cell types was completed by an independent pathologist from US Biomax, Inc. Each core 
was scanned by the Aperio Scanning System at ×20. The total number of positive cells and the 
intensity of anti-NEDD9 staining were computed by Aperio ImageScope10.1 software based on 
the digital images taken from each core. 
Western blot procedure and antibodies
Western blotting procedures were previously described (26). Primary antibodies included anti-
NEDD9 monoclonal antibody (mAb; 2G9; ref. 19), anti-NEDD9 (p55, custom made using 
NEDD9 1–394 aa as an antigen), anti-?-actin mAb, or anti-GAPDH (Sigma); anti-AURKA (BD 
Biosciences); anti-AURKA (AurA-N, custom made using 1–126 aa N-terminal fragment of 
AURKA), anti-phospho-T288 Aurora A (Cell Signaling); and anti-histone H3, and anti-phospho-
Ser10 histone H3 and anti-ubiquitin (Millipore, BD Biosciences). Blots were developed by the 
HyGLO HRP Detection Reagent (Denville Scientific, Inc.). Bands were digitized and quantified 
using a digital electrophoresis documentation and image analysis system (G-box, Syngene 
Corp.). 
Protein expression, GST pull-down, and immunoprecipitation
In vitro pull-down and immunoprecipitation protocols were previously published (19, 26). 
Immunoprecipitation samples were incubated with anti-AURKA (AurA-N) or anti-NEDD9 (p55), 
immobilized on the A/G-protein Sepharose or 4B-Glutathione agarose for GST pull-down (G&E 
Healthcare Life Sciences) at 4°C, washed and resolved by SDS-PAGE. His-tagged cdh1 protein 
(Novus International, Inc.), 50 ng of recombinant AURKA and GST-HEF1 in AURKA buffer were 
used in the cdh1 titration pull-down. 
Animal studies
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient mice were purchased from the 
Jackson Laboratory (stock 5557). Animals were housed in the WVU Animal Facility 
(Morgantown, WV) under pathogen-free conditions; protocol approved by the Institutional 
Animal Care and Use Committee. Primary tumor and organs with metastases were collected, 
processed, and analyzed by the WVU Department of Pathology Tissue Bank Core Facility. 
Animal bioluminescence imaging
Mice were injected with luciferase-expressing MDA-MB-231LN cells and imaged weekly for 
quantitative evaluation of tumor growth and dissemination. About 150 mg/kg d-luciferin (Caliper 
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Life Sciences) was injected into the peritoneum. Images were obtained using the IVIS Lumina-II 
Imaging System and Living Image-4.0 software. 
1. Mammary fat pad injections: For animal studies, cells were grown, trypsinized, 
resuspended in DPBS (1 × 107 cells/mL), and 0.1 mL was injected into the fourth 
inguinal mammary gland of female mice 6 to 8 weeks of age and followed by 
bioluminescence imaging (BLI) up to 6 weeks. 
2. Tail vein injections: Males were intravenously injected with 1 × 105 cells and followed by 
BLI once a week for 2 to 3 weeks total. Total radiance of lungs was calculated at each 
time point in control and treated animals. Lungs were imaged, fixed in formalin at the 
end point of study, and analyzed for number and size of metastases by a pathologist. 
Tumor volume measurement
Tumor size was assessed by Vevo2100 Micro-Ultrasound System. A 40 or 50 mHz transducer 
was used, depending on the tumor size, and a 3-dimensional image (3D) was acquired with 
0.051 mm between images. Using the integrated software, the images were reconstructed to 
create a 3D image of the tumor. 
AURKA inhibitors application
Cell line studies.
Cells were treated with MLN8054 (0–100 nmol/L) or PHA-680632 (0–400 nmol/L) inhibitors 
(Selleckchem) for 2 to 12 hours, disrupted in protein Triton-based cell lysis buffer (19)
processed for Western blotting or immunofluorescence staining. 
Xenograft studies.
Compound administration began (i) when primary tumors reached 150 to 200 mm3 in female 
mice or (ii) 24 hours postintravenous injection of tumor cells in male mice. MLN8237 is an 
improved analog of MLN8054 compound with increased stability suitable for in vivo studies. 
MLN8237 was dissolved in 10% 2-hydroxypropyl-b-cyclodextrin, 1% sodium bicarbonate in 
water. About 20 mg/kg/dose was administered via oral gavage twice daily for 4 days/week for 2 
weeks. MLN8237 was tested against a placebo control consisting of drug vehicle. 
Statistical analysis
Unpaired t test, nonlinear regression, or 1- or 2-way ANOVA with Tukey's multiple comparisons 
were used for statistical analysis of the results. Experimental values were reported as SEM. 
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Differences in mean values were considered significant at P < 0.05. Rates of tumor growth were 
established by linear regression of the bioluminescence data with time and cohort membership
as covariates. Statistical calculations were conducted using the GraphPad InStat software 
package. 
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Results
Increased NEDD9 expression tightly correlates with expression of AURKA protein in 
breast cancer.
AURKA and NEDD9 are independently overexpressed in many human cancers (1–3,
16–18). We have previously shown that NEDD9 binds to and activates AURKA in cancer cells 
(19), and expression of AURKA alone was found to be an independent prognostic marker of 
poor survival. To determine whether the expression of both proteins could facilitate the 
diagnosis of certain types or stages of breast cancer, we conducted IHC staining for NEDD9 
and AURKA in 120 cases of breast cancer. Cases screened from a tissue microarray consisted 
of 4 groups of progressive disease stages: (i) normal tissue, (ii) intraductal carcinoma (IC), (iii) 
invasive ductal carcinoma (IDC), and (iv) metastatic IDC (MIDC; Supplementary Table S1). 
Representative images of IHC staining for each group are shown in Fig. 1A. Statistical analysis 
of staining intensity suggests that NEDD9 and AURKA expression positively correlate. The 
lowest expression and intensity of either protein was found in normal tissue, whereas a 10- to 
20-fold increase in expression was observed in tumor samples (Fig. 1B). Significant correlation 
between NEDD9 and AURKA expression was noted for all 4 evaluated tissue types (Fig. 1C). 
The Spearman correlation coefficients for the normal, IC, IDC, and MIDC groups are 0.85, 0.67, 
0.63, and 0.59, respectively, indicating a positive correlation (Fig. 1C). A random forest fit of 
NEDD9 and AURKA positivity staining, which achieved an out-of-bag error rate of 0.508, 
indicates that by using NEDD9 and AURKA positivity scores, one can double the predictive 
power over chance (Fig. 1D). To define the molecular mechanisms underlying NEDD9 and 
AURKA correlative expression profiles, we used a panel of human breast cancer cell lines 
where the levels of NEDD9 can be manipulated and controlled. 
 
Depletion of NEDD9 leads to dramatic decrease of AURKA protein in cells lines and 
animal models
The expression profiles of AURKA and NEDD9 in a panel of human breast cancer cell 
lines followed a pattern similar to that observed in the tissue microarray analysis. Invasive MDA-
MB-231 (or highly invasive lymph node–derived MDA-MB-231LN), MDA-MB-453, and ZR-75-1
cell lines had the highest levels of expression of NEDD9 and AURKA, followed by BT-549, and 
noninvasive MCF7 and BT-20 lines (Fig. 2A). We next evaluated AURKA protein levels in
mouse embryonic fibroblasts derived from NEDD9 knockout (KO) and wild-type (WT) animals. 
AURKA expression levels were reduced in KO cells compared with WT cells (Fig. 2B). Similar 
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results were obtained by IHC analysis of tissue sections (Fig. 2C), suggesting that maximal 
expression of AURKA is dependent on NEDD9. 
Depletion of NEDD9 by 2 different shRNAs or siRNAs reduced the levels of AURKA 
protein by 60% to 80% (Fig. 2D; Supplementary Fig. S1A). To determine whether the reduced 
levels of AURKA were due to transcriptional mechanisms or nonspecific siRNA depletion, we 
carried out qRT-PCR analysis for NEDD9 and AURKA. The NEDD9-targeting siRNAs did not 
affect the levels of AURKA mRNA (Supplementary Fig. S1B), indicating that NEDD9 regulates 
AURKA at the protein level. Moreover, we were able to restore AURKA protein levels in 
shNEDD9 cells via re-expression of doxycycline-inducible WT-NEDD9 cDNA (Fig. 2E). 
Protein levels of NEDD9 and AURKA are tightly regulated during the cell cycle (28); 
therefore, we examined the effects of NEDD9 depletion on the cell cycle. FACS analysis of cells 
treated with siRNA targeting NEDD9 did not show significant difference in cell-cycle distribution 
when compared with siCon (Supplementary Fig. S1C). These results indicate that the decrease 
in AURKA protein level is NEDD9-dependent and is post-transcriptionally regulated. 
NEDD9 regulates the stability of AURKA
To further evaluate how NEDD9 governs AURKA expression, we examined AURKA 
levels in shCon- and shNEDD9-MDA-MB-231LN cells treated with the protein synthesis inhibitor 
cycloheximide. Cycloheximide treatment led to an abrupt decrease in the amount of AURKA in 
shNEDD9 cells during the first 3 hours (Fig. 3A). shCon cells had elevated AURKA levels for 6 
hours and followed NEDD9 protein decay dynamics (Fig. 3A). The half-life of AURKA was 6 and 
3 hours in shCon and shNEDD9, respectively (Fig. 3B). The delayed decrease in AURKA 
protein levels in control cells compared with shNEDD9 indicates that AURKA protein stability is 
dependent on NEDD9. 
Decreased AURKA protein in NEDD9-deficient cells is caused by enhanced proteasome-
dependent degradation
NEDD9 and AURKA undergo ubiquitination and proteasomal degradation in a cell-
cycle–dependent manner (9, 20). To test whether the decrease in AURKA protein levels is 
associated with increased proteasome-based degradation, cell lines with depleted NEDD9 were 
treated with the proteasome inhibitor MG132 (Fig. 3C). Inhibition of proteasomal activity 
restored levels of AURKA in shNEDD9 cells to that of control cells (Fig. 3C and D), suggesting 
that NEDD9 protects AURKA from ubiquitination- and proteasome-dependent degradation. To 
directly test this, AURKA was immunoprecipitated from shNEDD9 and control cells and 
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analyzed by immunoblotting with anti-AURKA and antiubiquitin antibodies. Depletion of NEDD9 
increased the amount of ubiquitinated AURKA (Fig. 3E and F). Similar results were obtained 
with original MDA-MB-231 cells. Moreover, reexpression of wild-type NEDD9 was able to 
rescue this phenotype and decrease ubiquitination of AURKA (Supplementary Fig. S1E and 
S1F). NEDD9-dependent decrease in AURKA ubiquitination could be caused by steric 
hindrance of bound NEDD9 or by titration of ubiquitination machinery components, as both 
proteins use the APC/C–cdh1 complex (8, 20). To distinguish between these 2 possibilities, the 
levels of other APC/C–cdh1 targets, including Plk1 and Cdk1, in shNEDD9 cells were evaluated 
by immunoblotting. No difference in Plk1 and Cdk1 expression was detected between shNEDD9 
and controls cells (Supplementary Fig. S1D), indicating that NEDD9 specifically targets AURKA 
and does not affect stability of other APC/C–cdh1 substrates. We have previously shown that 
NEDD9 binds to the N-terminal domain of AURKA containing the A-box motif (19), which is 
required for cdh1 binding and ubiquitination by APC/C (7, 8). To test this hypothesis, we used 
recombinant NEDD9, cdh1, and AURKA in in vitro GST pull-down assay and examined whether 
the presence of NEDD9 imposes its inhibitory action on cdh1 directly. We confirmed that 
NEDD9 was able to bind AURKA in vitro in the presence of excess cdh1 and titrated cdh1 from 
the complex with AURKA in a concentration-dependent manner (Fig. 3G and H). Thus, the 
presence of NEDD9 potentially increases AURKA protein levels by protecting AURKA from 
binding cdh1 resulting in reduced AURKA ubiquitination and subsequent proteasomal 
degradation. 
NEDD9 binding to AURKA is necessary for protein stabilization
Phosphorylation of NEDD9 at S296 and S298 by AURKA impedes formation of the 
NEDD9/AURKA complex (19). To determine the impact of NEDD9 binding on AURKA protein 
levels, individual and dual phosphorylation null S296A-(A), S296A/S298A-(AA) and mimetic 
S296E-(E), S296E/S298E-(EE) forms of NEDD9 were generated. Indicated mutants were 
transfected in HEK293T cells followed by immunoprecipitation of AURKA (Fig. 4A). 
Immunoprecipitation analysis showed a reduction in binding to AURKA by the NEDD9 
phosphomimetic (E, EE) mutants, whereas phosphorylation null (A, AA) NEDD9 mutants 
showed increase in AURKA binding (Fig. 4A and B), in agreement with our previously published 
observations (19). The increase in binding by phosphorylation-null mutants in this setting is 
expected because of overexpression of NEDD9 in HEK293T cells and inability of 
AURKA/NEDD9-AA complex to dissociate. To test the ability of these mutants to rescue the 
levels of AURKA in shNEDD9 cells, the 2 NEDD9 mutants (AA, EE) were overexpressed in an 
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inducible manner and AURKA levels were measured by Western blotting (Fig. 4C and D). 
Reexpression of the AA mutant was sufficient to restore the levels of AURKA protein, 
meanwhile, the EE mutant failed to restore the levels of AURKA to control levels due to its 
inability to bind AURKA. Therefore, binding of NEDD9 to AURKA is necessary to stabilize 
AURKA. 
NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro and in in 
vivo xenografts 
Because of the structural proximity of the ATP-binding pocket to the NEDD9-binding 
domain on AURKA (23), we hypothesized that NEDD9-AURKA binding could potentially 
interfere with binding of AURKA inhibitors, in addition to preventing cdh1 binding. MLN8054 and 
PHA-680632 are ATP-competitive AURKA inhibitors that are currently in phase II clinical trials 
that have shown some efficacy against hematopoietic malignancies but have minimal effects 
against solid tumors (29–31). To evaluate the impact of NEDD9 expression on therapeutic 
outcome, NEDD9 was knocked down in breast cancer cell lines with high NEDD9 expression 
before treatment with PHA-680632 or MLN8054. NEDD9 depletion increased the efficacy of 
both inhibitors (Fig. 5A), decreasing the IC50 of PHA-680632 from 150 nmol/L in control cells to 
50 to 100 nmol/L in shNEDD9 cells (Fig. 5B), as determined by the amount of active phT288-
AURKA. Similar results were obtained with MLN8054, where the IC50 value decreased from 
200 nmol/L (shCon) to 20 nmol/L (shNEDD9; Fig. 5C and D). Inhibition of AURKA function was 
further confirmed by analysis of histone H3 phosphorylation in treated shCon and shNEDD9 
cells. Inhibition of AURKA leads to accumulation of cells in mitosis characterized by 
phosphorylation of histone H3 at Ser10 (Fig. 5B and D and Supplementary Fig. S2E). The 
concentration of PHA-680632 was limited to 400 nmol/L to avoid targeting AURKB, which might 
lead to decrease in phosphorylation of histone H3. 
NEDD9 depletion alone or in combination with AURKA inhibitors reduces tumor burden 
and lung metastasis
To examine the validity of our findings in in vivo xenograft models of human breast 
cancer, we used MDA-MB-231LN cells and shRNAs targeting NEDD9 or control. Tumor cells 
were injected into the mammary fat pad of NSG female mice and the tumor growth was 
assessed using BLI (Fig. 6A and B). The original MDA-MB-231LN cell line was tested and 
showed similar NEDD9 expression, tumor growth, and metastasis kinetics when compared with 
MDA-MB-231LN-shCon cells (Fig. 6A and B and Supplementary Fig. S1F). On the basis of 
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these results, we have concluded that the MDA-MB-231LN-shCon cell line is a proper control 
and we used it in the subsequent experiments. Depletion of NEDD9 alone reduced tumor 
burden by 15% to 20% (Fig. 6B) and reduced the number of metastases in lungs by 25% to 
50% (Fig. 6D and E shCon-V, shN2-V and Supplementary Fig. S2A). 
Next, we combined shNEDD9 and AURKA inhibitor (MLN8237, a more stable analog of 
MLN8054) to test whether the combination will increase the efficacy of MLN8237 against 
primary tumor and metastasis (Fig. 6C–E). Treatment was initiated when primary tumor volume 
reached 150 to 200 mm3, based on ultrasound measurements in each cohort (30). 
Representative images and quantification of tumor volume is shown in Supplementary Fig. S2B 
and S2C. Difference in the rates of tumor growth among the 4 groups was assessed by BLI and 
pathology measurements using linear regression analysis with time, cell line, and treatment as 
covariates. Application of MLN8237 alone did not lead to a decrease in primary tumor growth, 
but in combination with shNEDD9, efficacy was improved 2-fold (Fig. 6C). Surprisingly, 
treatment with MLN8237 alone significantly decreased the number of lung metastases with a 2-
fold greater response in shNEDD9-expressing cells (Fig. 6D and E; Supplementary Fig. S2D). 
Next, we used intravenous injection of breast cancer cells in NSG male mice to 
determine the impact of AURKA inhibitor on colonization by circulating tumor cells. On the basis 
of BLI data (Fig. 7A–C) and study endpoint pathology reports on dissected lungs 
(Supplementary Fig. S2F), shNEDD9-expressing cells were extremely sensitive to MLN8237 
and were not capable of initiating tumor growth in lungs when compared with vehicle-treated 
cells. In summary, depletion of NEDD9 sensitizes human xenografted tumors and circulating 
tumor cells to AURKA inhibitors and eliminates metastasis to the lungs. Collectively, our data 
suggest a model (Fig. 7D) in which overexpression of NEDD9 renders AURKA less susceptible 
to Cdh1-APC–mediated ubiquitination and binding of small-molecule ATP-competitive inhibitors, 
thus protecting it from degradation and drug applications. 
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Discussion
Recent studies corroborate overexpression of NEDD9 specifically with breast cancer 
and melanoma metastasis (16–18). Our data indicate that NEDD9 expression levels correlate 
positively with oncogenic AURKA expression and activation. Both proteins were correlated with 
pathologic parameters in human breast cancer cell lines and breast cancer patient samples. 
Moreover, achieving 80% accuracy for predicting cancer stage invasiveness is possible when 
screening for expression of both proteins. 
AURKA inhibitors have recently entered phase II clinical trials for cancer treatment. 
However, the best response achieved in advanced tumors is disease stabilization, as tumor 
regression has not been reported (29–32). The knowledge of the molecular factors that 
influence AURKA stability and, therefore, sensitivity and resistance to AURKA inhibitors remains 
limited. With a few exceptions, such as TPX2 and PUM2 (13, 14), the role of AURKA activators 
in the stability of AURKA and their impact on sensitivity to AURKA inhibitors is unknown. 
We show here that NEDD9 is a critical component in AURKA activation and stability. 
Furthermore, the molecular mechanism by which NEDD9/AURKA signaling functions to 
increase breast tumor cell resistance to AURKA inhibitors has been elucidated. Overexpression 
of NEDD9 in breast cancer cells prevents proteolytic degradation of AURKA and results in 
upregulation of AURKA protein level. AURKA activation correlates with protein stabilization, 
which in turn directly depends upon APC/C complex and its substrate recognition subunit, cdh1. 
Direct binding of NEDD9 to AURKA hampers the ability of the APC/C complex to ubiquitinate 
AURKA by preventing cdh1 binding. A NEDD9-dependent increase in AURKA protein and 
activity is critical for G2–M transition. Interestingly, the majority of proteins activating and/or 
stabilizing AURKA reside in the nucleus (Bora, TPX2, Ajuba, etc.) or require prior modifications 
(TPX2/AURKA binding is stimulated by the GTPase Ran) including phosphorylation by AURKA 
for binding (33–36). Nevertheless, a NEDD9-driven increase in the total amount of AURKA 
would be less noticeable in mitosis due to the inactivity of cdh1 (8). The excess of NEDD9 
protein might promote the binding of known AURKA partners such as Ajuba, TPX2, and Bora 
(33, 34) leading to increased loading of AURKA on microtubules and Plk1 activity (37) and 
cancer progression. Direct binding of NEDD9 at the N-terminal domain decreases the efficacy of 
AURKA inhibitors in cell culture and in mammary tumor xenografts. Deletion or mutation of 
NEDD9 dramatically decreases AURKA protein level and kinase activity. Phosphorylation of 
NEDD9 by AURKA at Ser296 serves as a negative feedback loop to regulate the levels of active 
AURKA. The abundance of NEDD9 in epithelial cancers and dephosphorylation by PP2A (21)
creates a constant supply of unphosphorylated NEDD9 that would stabilize and activate 
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AURKA. We found that depletion of NEDD9 reduces tumor cell proliferation and lung 
metastases of orthotopic human tumor xenografts. Finally, we have established that treatment 
with AURKA inhibitors is particularly efficient against metastasis. In combination with shNEDD9 
RNAs, MLN8237 abolishes lung metastases from orthotopic xenograft models as well as in lung 
colonization assays. No significant changes in animal weight and no apparent toxicity were 
noticed, suggesting a favorable toxicity profile. 
The correlation of AURKA and NEDD9 expression in cancer patient biopsies could be 
critical for diagnostic purposes. It could potentially be used to predict the sensitivity of these 
patients to AURKA inhibitors. In addition, our results advocate the development and 
investigation of new NEDD9-targeting compounds as a novel therapeutic strategy against 
metastatic breast cancer. 
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Figure Legends
Figure 1. Increased NEDD9 expression correlates with expression of AURKA protein in 
invasive ductal breast adenocarcinomas. A, representative images of IHC staining of tissue 
microarray with anti-AURKA (top) and anti-NEDD9 (bottom) antibodies. Normal breast tissue, 
intraductal carcinoma (IC), invasive ductal carcinoma (IDC), metastatic invasive ductal 
carcinoma, lymph nodes (MIDC-?????????????????????????????????????????????????????????????
indicated in the main panel. B, quantification of NEDD9 and AURKA in relative units of positivity 
(RUP; percentage of cells stained positively in the same core stained by anti-AURKA or -
NEDD9 antibodies). Most fitted lines were plotted on the graphs. C, positivity data for both 
proteins were analyzed using Spearman Rho correlation. D, positivity data for both proteins 
were analyzed by random forest statistical software.
Figure 2. Depletion of NEDD9 leads to dramatic decrease of AURKA protein. Western blot 
analysis of NEDD9 and AURKA in breast cancer cell lines (A) and mouse embryonic fibroblasts 
(B) derived from wild-type (WT) and NEDD9 knock out (KO) animals. C, representative IHC of 
anti-AURKA staining in kidney tissues, WT, and NEDD9-KO mice. Staining with nonspecific IgG 
??????????????????????????D, Western blot analysis and quantification of AURKA, NEDD9, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) upon treatment with anti-NEDD9 (shN1, 
shN2) or nonspecific (shCon) shRNAs, n = 3, percentage of AURKA expression to shCon, ± 
SEM. Student one-tailed t test: **, P = 0.0006; **, P = 0.0024 (shCon/shN1 or/shN2) and no 
significant difference (ns; shN1/shN2) in MCF7. **, P = 0.003; **, P = 0.0094 (shCon/shN1 
or/shN2) and ns (shN1/shN2) in MDA-MB-231. E, WB analysis and quantification of AURKA 
and NEDD9 expression in shNEDD9 and shCon cells transfected with WT-NEDD9 or control-
RFP (red fluorescent protein) cDNA; n = 3, percentage of AURKA expression to shCon, 
normalized by GAPDH. Student one-tailed t test: *, P = 0.0186; **, P = 0.0012 (shCon/shN1 
or/shN2), ns (shN1/shN2 or shN1/NEDD9 and shN2/NEDD9 reexpression).
Figure 3. NEDD9 regulates stability of AURKA through inhibition of proteasome-dependent 
degradation. A, Western blot analysis of AURKA and NEDD9 expression in shCon-, shNEDD9-
MDA-MB-231LN cells ?????????????????????? ???????????????????????????????????-tubulin. B,
quantification of AURKA as in A, n = 3, fold of change of AURKA expression to time point 0 
hours, ±SEM, one-way ANOVA: ***, P < 0.0001; **, P = 0.005 (shCon/shN1 or/shN2) at each 
time point (except 0 hour). C, Western blot analysis of AURKA, NEDD9 in shCon, shNEDD9 
cells treated with MG132 or vehicle. D, quantification of AURKA expression as in C (+MG132), 
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n = 3, fold of change to shCon, ±SEM. Student t test: **, P = 0.0086; **, P = 0.0084
(shCon/shN1 or/shN2). E, Western blot analysis of AURKA ubiquitination in WCL and 
immunoprecipitation (IP) from shCon or shNEDD9 cells transfected with pcDNA3-Myc-Ubiquitin, 
with MG132. F, quantification of AURKA ubiquitination as in E, IP, n = 3, fold of change to 
shCon, ±SEM. Student t test: **, P = 0.0098; *, P = 0.05 (shCon/shN1 or/shN2). G, WB with 
anti-AURKA, anti-NEDD9, and anti-cdh1 antibodies. H, quantification of AURKA using the 
following formula (AURKA-IP/AURKA-total) normalized to NEDD9 pull-down as in G, n = 3, 
plotted as AURKA ratio ± SEM, *, P < 0.05.
Figure 4. NEDD9 binding to AURKA is necessary for protein stabilization. A, Western blot 
analysis of AURKA and NEDD9 expression in WCL (left) or IP-GFP (right) from 293T cells 
transfected with pAcGFP-NEDD9-WT, AA, EE A, E, mutants, or GFP control. B, quantification 
of AURKA-coIP as in A, n = 3, plotted as percentage ± SEM. AURKA-coIP with wtNEDD9 
assigned 100%. Student t test: **, P = 0.0013; *, P = 0.010; **, P = 0.00209, ns (WT/AA or/EE 
or/A or/E, respectively). C, WB analysis of AURKA and NEDD9 expression in WCL of MDA-MB-
231 cells expressing doxycycline-inducible NEDD9-AA, -EE, or empty vector control. D,
quantification of AURKA expression as in C, n = 3, relative intensity units (RIU) ± SEM, 
normalized to actin. Two-way ANOVA: P < 0.0001. Student t test: **, P = 0.0063, 0.0061 [AA/EE 
(+Dox, 24, 48 hours)].
Figure 5. NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro. A,
Western blot analysis of AURKA, phT288-AURKA, NEDD9 in shCon or shNEDD9-MDA-MB-
231LN cells treated with PHA-680632. B, quantification of phT288-AURKA expression as in A, n
= 3, normalized to total AURKA and plotted as relative intensity units (RIU) ± SEM. Two-way 
ANOVA: P < 0.0001, (shCon/shN1 or shN2), P = 0.0013 (shN1/shN2). Quantification of phS10-
Histone H3 (IF), n = 3, 1000 cells/treatment, P = 0.006, P = 0.0067 (shCon/shN1 or shN2), no 
significant difference (shN1/shN2; C). Western blot analysis of total AURKA, phT288-AURKA, 
NEDD9 expression in cells treated with increasing concentrations of MLN8054. D, quantification 
as in B for the Western blots shown in C. P < 0.0001, (shCon/shN1 or shN2), P = 0.0041 
(shN1/shN2). Quantification of immunofluorescence shown in Supplementary Fig. S2E, n = 3, 
1,000 cells/treatment, P = 0.0053, P = 0.0086 (shCon/shN1 or shN2), no significant difference 
(shN1/shN2).
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Figure 6. Depletion of NEDD9 combined with AURKA inhibitors leads to decrease in a tumor 
burden and lung metastasis in breast cancer xenograft model. A, representative images of BLI 
of mice orthotopically injected with MDA-MB-231LN parental, shCon, or shNEDD9 (shN2) cells. 
B, quantification of BLI data as in A plotted as mean log photon flux ± SEM. Linear regression 
analysis, P = 0.0021, P = 0.0006 (shCon/shN2), weeks 3 and 4; no significant difference 
(shCon/parental). C, quantification of BLI data, mice orthotopically injected with shNEDD9 or 
shCon cells and treated with MLN8237 (MLN) or vehicle, 3 independent experiments, n = 6 in 
each group; mean photon flux, ± SEM. Two-way ANOVA, P = 0.0061 (shCon-MLN/shN2-MLN, 
days 7–11). D, representative images of BLI, lungs dissected from 4 groups. E, quantification of 
BLI data as in D, 3 independent experiments, n = 6/group; mean photon flux ± SEM. Two-way 
ANOVA: **, P = 0.0071 (shCon-Vehicle/shN2-Vehicle); **, P = 0.045 (shCon-MLN/shN2-MLN).
Figure 7. Combination of AURKA Inhibitors with depletion of NEDD9 reduces colonization 
potential of human circulating tumor cells in lungs. A, representative images of BLI; mice 
intravenously injected with MDA-MB-231LN cells expressing shCon or shNEDD9 (shN2) and 
treated with MLN8237 (M) or vehicle (V). B, quantification of BLI data as in A, 3 independent 
experiments, n = 6/group, plotted as fold growth of BLI mean radiance ± SEM. Two-way 
ANOVA: P < 0.0001 (shCon-V/shCon-M), (shN2-V/shN2-M), (shCon-V/shN2-V); P = 0.0145 
(shCon-M/shN2-M). C, quantification of BLI as in A, dissected lungs; 3 independent 
experiments, n = 6/group, mean photon flux ± SEM. One-tailed Student t test: P < 0.0001 
(shCon-V/shCon-M), (shN2-V/shN2-M), P = 0.009 (shCon-V/shN2-V), P = 0.0335 (shCon-
M/shN-M). D, model of NEDD9 action on AURKA stability and inhibitors competitive binding 
(I/III). Under normal physiologic conditions with low NEDD9 expression, AURKA is not solely 
bound to NEDD9 and gets targeted by cdh1 and AURKA inhibitors (II/IV). Overexpression of 
NEDD9 leads to sequestering of AURKA by NEDD9 and limits cdh1 binding, thus stabilizing 
AURKA and hampers the ability AURKA inhibitors to access ATP pocket.
Supplementary Figure 1. Depletion of NEDD9 with siRNA does not affect transcription or 
cell cycle distribution, but decreases AURKA protein levels. (A). Western blot analysis of 
AURKA and NEDD9 protein levels in MCF7 cells transfected with siCon or siNEDD9 smart pool. 
Quantification of AURKA and NEDD9 proteins is shown on the right panel. (B). Quantitative 
PCR analyisis (qPCR) of NEDD9 and AURKA mRNA levels after siRNA treatment and in (A). 
One tailed Students t-test of aurka mRNA levels indicates no statistically significant difference 
(ns) between siNEDD9 and control, p=0.327 between siCon and siNEDD9. (C). Flow cytometry 
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analysis of cell cycle distribution of siNEDD9 and siCon treated cells. (D). Western blot analysis 
of NEDD9, CDK1, cyclin B (CKB), PLK1 and actin expression levels in MDA-MB-231 cells 
expressing siControl or siNEDD9 (smart pool, 4 siRNAs). (E). WB analysis of NEDD9, AURKA 
and ubiquitinated AURKA in MDA-MB-231 cells expressing shCon, shNEDD9 (shN1) and shN1 
rescued with exogenouse expression of wt HA-tagged NEDD9 cDNA. (F). WB analysis of 
NEDD9, AURKA and GAPDH in MDA-MB-231 and MDA-MB-231LN cells.
Supplementary Figure 2. Combination of AURKA inhibitors with Depletion of NEDD9 
dramatically reduces metastasis to lungs. (A). Quantification of number of metastasis in 
lungs of orthotopically injected animals at the end of the study. Results were plotted as mean 
number of metastases per mm2 +/-S.E.M from 3 independent experiments with n=6 per 
treatment group. Two way ANOVA indicated statistically significant difference p=0.048 only for 
shCon-M and shN2-M, the rest was ns. (B). Representative images of Vevo200 ultrasound 3D 
reconstructed tumors from siNEDD9 (14 days) and siCon (8-10 days) orthotopically injected 
mice. Scale bar 1mm. (C). Quantification of tumor volume before application of MLN8237. 
Treatment was initiated upon similar volumes were reached in all 4 groups (time point zero for 
MLN treatment). One way ANOVA, did not identified any significant difference between the 
groups (ns). (D). Quantification of number of metastasis in lungs of intravenously injected 
animals at the end of the study of shCon and shNEDD9 (shN2) treated with MLN8237 (MLN) or 
vehicle alone at the end of the study. Results were plotted as average number of metastases 
per mm2 +/-S.E.M from 3 independent experiments with n=6 per group. Two way ANOVA 
indicated statistically significant difference p=0.045 only for shCon-M and shN2-M, the rest was 
ns. (E). Representative images of immunofluorescent staining with anti-phSer10-Histone H3 
antibodies (magenta), DNA (dapi, cyan) and GIPZ-shRNAs (green) of shCon and shNEDD9 
(shN1) MDA-MB-231LN cells. The scale bar is 10 ????
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Abstract
The scaffolding protein NEDD9 is an established pro-metastatic marker in several cancers.
Nevertheless, the molecular mechanisms of NEDD9 driven metastasis in cancers remain ill
defined. Here, using a comprehensive breast cancer (BCa) tissue microarray, it was show that
increased levels of NEDD9 protein significantly correlated with the transition from carcinoma in
situ to invasive carcinoma. Similarly, it was shown that NEDD9 overexpression is a hallmark of
highly invasive BCa cells. Moreover, NEDD9 expression is crucial for the protease-dependent
mesenchymal invasion of cancer cells at the primary site but not at the metastatic site. 
Depletion of NEDD9 is sufficient to suppress invasion of tumor cells in vitro and in vivo, leading 
to decreased circulating tumor cells (CTCs) and lung metastases in xenograft models.
Mechanistically, NEDD9 localized to invasive pseudopods and was required for local matrix
degradation. Depletion of NEDD9 impaired invasion of cancer cells through inactivation of
membrane-bound matrix metalloproteinase MMP14 by excess TIMP2 on the cell surface.
Inactivation of MMP14 is accompanied by reduced collagenolytic activity of soluble
metalloproteinases MMP2 and MMP9. Re-expression of NEDD9 is sufficient to restore the
activity of MMP14 and the invasive properties of BCa cells in vitro and in vivo. Collectively,
these findings uncover critical steps in NEDD9-dependent invasion of BCa cells. Implications: 
This study provides a mechanistic basis for potential therapeutic interventions to prevent 
metastasis.
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Introduction
The cytoplasmic docking protein, NEDD9 has emerged as a biomarker of melanoma, 
pancreatic, and lung cancer metastasis and is required for the migration of tumor cells (1-6). 
The overexpression of NEDD9 leads to mesenchymal protease-dependent migration (4, 7). 
NEDD9 promotes epithelial-mesenchymal transition (EMT) and invasion of BCa cells (8).
Extracellular matrix (ECM) proteolysis is dependent upon soluble and membrane bound 
matrix metalloproteinases (MMPs) (9). Membrane bound MMP14 is a key enzyme involved in 
ECM degradation and invasion of tumor cells. The activity of MMP14 is regulated by 
phosphorylation, proteolysis, and endocytosis (10-11). MMP14 is activated by furin and is 
inhibited by tissue inhibitor of MMP, TIMP2, which makes a stable complex with the activated 
MMP14 (12-13). The tertiary complex of MMP14, TIMP2, and proMMP2 is required to form on 
the cell surface to activate MMP2 by a neighboring MMP14 free of TIMP2 (14). The presence of 
excess TIMP2 results in inhibition of MMP14 activity and decreased processing of proMMP2 to 
active MMP2 (15). In invasive cancer cells, MMP14 is localized at the membrane of 
invadopodia, ventral actin-based membrane protrusions (16-17). Local ECM degradation is 
initiated upon the assembly of: F-actin, cortactin, N-WASP, and the Arp2/3 complex (17-18). 
Functional mature invadopodia form when F-actin and cortactin-rich puncta initiate the 
accumulation of MMP14, thus forming proteolytically active protrusions (16). Activity of MMP14 
is required for invasion of 3D collagen matrices in tissue culture and in nude mice (19- 20).
While NEDD9 deficient cells are characterized by reduced migration accompanied with 
reduced levels of Src and FAK kinase activity (21-22) the role of NEDD9 in the function of 
invadopodia in BCa has been unclear. Although NEDD9 and another Cas family member, 
p130Cas, were previously identified in invadopodia of cancer cells (23-25), the differences 
between NEDD9 and p130Cas function in invasion are currently unknown.
In transgenic oncogene driven mammary tumor models such as MMTV-PyVmT or
MMTV-Her2/Erb2 genetic ablation of NEDD9 leads to delays in tumor initiation and growth but
has a limited effect on metastasis (21-22). The tumors arising in MMTV-Her2/NEDD9-/- or
PyVmT/NEDD9-/- mice underwent a dramatic mutational selection that overcame the initial
requirement for NEDD9. In this context it is difficult to determine the requirement for NEDD9 in
metastasis since the selection of alternative signaling pathways happened prior to tumor
formation. Also, it is currently unknown what stages of metastasis are affected by NEDD9.
Overexpression of NEDD9 is often mentioned in diverse cancers (1-4). However, as of 
now, a comprehensive analysis of NEDD9 expression with respect to BCa progression has not 
been conducted; To address these questions, we analyzed NEDD9 protein expression in a 
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tissue microarray (TMA) consisting of 200 progressive BCa patient biopsies and in a panel of 
diverse BCa cell lines. We found that NEDD9 is overexpressed in invasive breast ductal 
carcinomas and invasive cell lines. We discovered that NEDD9 is involved in regulation of 
MMP14 activity on the cell surface, but not expression. Depletion of NEDD9 leads to decrease 
in proteolytic activity of soluble MMPs and transmembrane MMP14, resulting in the ablation of 
cancer cell invasion in vitro and in vivo. The decrease in activity was due to the association of 
MMP14 with its inhibitor TIMP2 on cell surface. Depletion of TIMP2 or MMP14 expression or 
addition of excess of recombinant TIMP2 to control cells led to a similar phenotype, suggesting 
that excessive TIMP2 bound to the MMP14 potentially is the primary reason for decreased 
invasion in carcinoma cells upon depletion of NEDD9.
Using inducible shRNAs against NEDD9 in xenograft models, we dissected particular 
stages of metastasis dependent upon NEDD9 expression and thus define the sensitive stages 
of tumor progression where anti-NEDD9 therapy could be applied to prevent metastasis. We 
found that reduction of NEDD9 expression in established tumors leads to a drastic decrease in 
MMPs activity and number of circulating tumor cells resulting in a decrease in the overall 
number and size of pulmonary metastases. Collectively, our findings suggest a novel 
mechanism for NEDD9 in accelerating cell invasion through regulation of MMP14 by TIMP2 
thus defining the new therapeutic approach for anti-metastatic strategies via manipulation of 
NEDD9 expression.
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Materials and methods
Plasmids and cell culture. Cell lines MDA-MB-231, MDA-MB-453, ZR-75-1, BT-549, MCF10A,
MCF7, AU-565, BT-20, were purchased from and authenticated by American Type Culture 
Collection (ATCC), MDA-231-LN (Caliper Life Sci.) and grown based on manufacturer’s 
recommendations. shRNA expressing constructs against NEDD9, control (sequences available 
upon request) and smart pool siRNAs against MMP14 and TIMP2 and siControl were 
purchased from ThermoFisher Scientific as ready to use siRNAs or in pGIPZ, or in doxycycline-
inducible pTRIPZ vectors. Lentiviral particles were prepared as previously described (26). For 
rescue experiments wild type cDNA of mouse NEDD9 was subcloned into pLUTZ lentiviral 
vector under doxycycline-inducible promoter (27). Cell medium and supplements were 
purchased from ATCC (Sigma).
MMP Antibody Array. MMP Antibody Arrays were purchased from RayBiotech, Inc. and 
assays were carried out according to the manufacturer’s protocol using whole cell lysate (WCL) 
and conditioned for 24h serum free medium (SFM). 
Fluorescent-gelatin degradation assay. Foci of degraded matrix were visible as dark areas 
that lack fluorescence in the FITC-gelatin matrix (Life Technologies). Cells with pseudopods 
were identified by the presence of at least one actin/cortactin aggregate within the cell. 
Degradation per cell area was analyzed using ImageJ (NIH) as described (16). At least 100 
cells were counted per each experimental condition. Data were pooled from multiple 
independent experiments.
DQ Collagen Assay. Cells expressing doxycycline-inducible shRNAs against NEDD9 and red 
fluorescent protein (RFP) embedded in DQcollagen I/IV combined with matrigel (BD 
Biosciences) to allow for cell tracing and dose-dependent manipulation of NEDD9 depletion. 
shRNA expression was induced for 72h. DQ collagen I/IV/matrigel assays were carried out 
according to a previously published protocol (28). Detailed protocol for data acquisition and 
analysis outlined in supplementary material.
EnzChek Gellatinase/Collagenese assay. Assay was purchased from Life Technologies and 
performed accordingly to manufacturer’s recommendations using shNEDD9 and shCon 
conditioned medium (24h). Fluorescence was measured at 485/545mn.
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Gelatin zymography. The gelatin zymography protocol was performed as previously described 
(16, 24). Briefly, 4ml of 24h conditioned media was collected from cells, concentrated using 
AmiconUltra-4 columns and 1/20 of original volume loaded on the Zymogram Gelatin Gels (Life 
Technologies) and developed according to the manufacturer’s recommendations.
MMP14-specific fluorogenic substrate degradation assay. 2x104 cells were plated on 96w 
plate, for 16 hours, followed by 1 hour in L15 media (Life Technologies). MMP14-specific 
????????????????????????????????????????????????????????????????????????????????????????????????
measured at 328/400mn every 5 minutes for 12 hours, using Synergy H4 Plate Reader 
(BioTek). Averaged background signal was subtracted, and data plotted curves described by 
equation for one site binding kinetics and fitted to each data set with the R2 of 0.8 The curves 
were significantly different between control and NEDD9 deficient cells according to the Extra 
sum ofsquares F test, p<0.0001.
ECM coated Boyden chamber invasion assays. Invasion assays were performed using BD 
FluoroBlok™ insets coated with matrigel (BD Biosciences). Cells were added to the top 
chamber in serum free media, 10%FBS supplemented MEM was added to the bottom chamber, 
and incubated for 8h. Once cells migrated through the matrix, they were labeled with Calcein 
AM (Life Technologies) and detected by fluorescence plate reader (Genios) at 485/530nm 
excitation/emission.
Cell viability Trypan Blue exclusion assay. MDA-MB-231-shCon, -shNEDD9 cells were 
cultured in suspension using Ultra-Low attachment plates (Fisher Scientific) for 36 hours; 0.1 
mL of a 0.4% solution of trypan blue in PBS was added to 1x106/mL of cells. The total number 
of cells and the number of blue staining cells were calculated by Countess automated cell 
counter (Life Technologies). Number of viable cells × 104 × 1.1 = cells/mL culture.
Fluorescence Activated Cell Sorting (FACS). 1x106 cells, with or without permeabilization by 
0.5% Tween20 (Sigma), were stained for MMP14 (Novus International). Secondary 
fluorescence conjugated antibodies (BD Biosciences) were used at a concentration 0.5ug/1 
x106 cells. Cells were pre-blocked with 5mg/ml of Human IgG (Sigma). As a control, non-
specific primary antibody, either Rabbit or mouse IgG were used (Sigma).
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Western blotting (WB). Western blotting was done using standard procedures (26, 30). 
Primary antibodies included mouse anti-NEDD9 mAb (2G9) (29), anti-phTyr, (Cell Signaling 
Technology Inc.), anti-p130Cas, -MMP2, -MMP9, -GAPDH, -RFP (ThermoFisher), anticortactin, 
-MMP14 (Novus), anti-?-actin, -?-tubulin, (Sigma) antibodies. Secondary HPRconjugated 
antibodies and chemiluminescence-based detection and quantification methods were previously 
described (30).Recombinant 
TIMP2 titration assay. Recombinant human TIMP2 was purchased from Life Technologies, 
diluted in cell culture medium and added to the cells in 0-100nM final concentration for 6-12h. 
After indicated times cells number of invaded cells was calculated as described in Boyden 
chamber invasion assay.
Immunofluorescence (IF). IF was performed as previously described (30). Primary antibodies 
included: rabbit anti-phTyr, -Arp3, -N-WASP (Cell Signaling Technology), anti-cortactin, -
MMP14 (Novus), anti-cortactin (4F11). The secondary antibodies included: Alexa Fluor 405, 
488, 555 donkey anti-rabbit, and Alexa Fluor 647 goat anti-mouse and Rhodamine-540 or 
PacificBlue-405-conjugated phalloidin (Life Technologies). Images were captured by confocal 
microscope LSM 510 (Carl Zeiss). To analyze IF data, volumes of positively stained structures 
were evaluated per cell. Quantifications were performed on z stack projections, and collected 
using standard acquisition parameters with ImageJ (NIH) and LSM Image analysis software 
(Carl Zeiss).
Tissue Microarrays (TMA) and Immunohistochemistry (IHC). The high density BCa tissue 
microarrays were purchased from US Biomax Inc., and content is outlined in Supplementary 
Table 1. All procedures were approved by the Institutional Biohazard Committee of West 
Virginia University. TMA sections were deparaffinized, endogenous peroxidase activity was 
quenched with 3% hydrogen peroxide, and slides were incubated with anti-NEDD9 antibodies 
(1:100 dilution) overnight at 4C; followed by staining with secondary peroxidase-labeled
antibodies and developed with DAB (DAKO). Positive and negative controls were included with 
each run. Staining was done in duplicate. The IHC analysis and scoring protocol is available in 
Supplementary materials.
Lung metastasis analysis. Lungs were collected and fixed in 4%PFA for 24-48h embedded in 
paraffin by WVU Tissue Bank as previously described (30). Serial 6-?????????????????????????
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eosin (H&E) staining. Metastatic lesions were visually identified and images were acquired 
using Zeiss Axioplan microscope with x4 and x10 NA1.6 objective, followed by higher x100 
magnification evaluation of whole section. Multiple sections from each lung/mouse were 
analyzed in each cohort. Quantification of the metastases was done by WVU pathologist (Dr. 
Livengood) using serial sections of lungs and H&E staining. Results are plotted as mean 
number of metastases per mm2 +/ S.E.M, 3 independent experiments, n=6-10 per treatment 
group.
Animal Studies. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ/(NSG) immunodeficient mice were 
purchased from the Jackson Laboratory. Animals were housed in the WVU Animal Facility 
under pathogen-free conditions and approved by the Institutional Animal Care and Use 
Committee protocol. Primary tumors and lungs were collected, processed for histopathology, 
and analyzed by the WVU Tissue Bank Core Facility.
Animal Bioluminescence Imaging (BLI) mammary fat pad injections. For orthotopic
injections luciferase-expressing MDA-MB-231LN and BT-549 cells expressing Control (Con) or 
NEDD9 (N1, N4) targeting shRNAs were grown, trypsinized, and resuspended in PBS (1×107 
cells/ml), and 0.1 ml was injected into the 4th inguinal mammary gland of 6-8 weeks old NSG 
female mice. Tumor cells were injected in 6 mice and the experiments were repeated at least 3 
times resulting in a total of 18 mice per cell line/per shRNA. Mice were imaged weekly for 
quantitative evaluation of tumor growth and dissemination for up to 6 weeks. For 
doxycyclineinducible shRNAs Dox diet (BioServ, S3888, 200mg/kg doxycycline) was introduced 
to start the shRNA expression when primary tumors in all experimental cohorts had reached 
similar size of 200mm3 (2-3 weeks post injection). shRNA expression was monitors by the 
increase in RFP fluorescence. 150 mg/kg D-Luciferin (Perkin Elmer) was injected into the 
peritoneum. Images were obtained using the IVIS® Lumina-II Imaging System and Living 
Image-4.0 software (Perkin Elmer).
Isolation and characterization of circulating tumor cells (CTC) from Peripheral Blood.
Blood was collected from ??? ????????????????????????????????????????????????????????????????
collected into centrifuge tubes containing anticoagulants (EDTA, heparin). Peripheral blood was 
depleted for erythrocytes using RBC Lysis buffer (eBiosciences) according to manufacturer’s
guidelines. The presence of nucleated tumor cells was detected by co-staining with DAPI and 
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quantified by direct fluorescence, of RFP-induced by Doxycycline only in tumor cells (red) was 
measured under fluorescence microscope.
Statistical Analysis. Statistical comparisons were made using two-tailed Student’s t test. When 
more than two groups were analyzed, one-way analysis of variance (ANOVA) was used. P??????
was considered to be significant. Experimental values were reported as the means with +/-
S.E.M. All calculations were made using the GraphPad InStat software. Random forests 
analysis provides an aggressive machine learning approach for classifying data into groups 
using ensembles of regression trees. Using this approach, we quantified the influence of 
NEDD9 IHC intensity staining in prediction of disease stage by the construction of the 
regression trees using a variable importance score averaged over all the trees.
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Results
Increase in NEDD9 protein correlates with an invasive state in BCa. To assess the role of 
NEDD9 in cancer progression, we screened two independent TMAs using immunohistochemical 
staining (IHC) comprised of 200 BCa cases. Figure 1A shows representative images of NEDD9 
staining in normal, DCIS (ductal carcinoma in situ), IDC (invasive ductal carcinoma), and MIDC-
LN (metastatic invasive ductal carcinoma, lymph node). Statistical analysis of anti- NEDD9 
staining intensity performed either by automated image capture system (Fig.1B) or visual 
evaluation by pathologist (Suppl.Fig.1A) suggests that NEDD9 levels positively correlate with 
disease progression. The lowest intensity was found in normal tissue, followed by a 10 fold 
increase in DCIS and a 30 fold increase in IDC, whereas only a 10 fold increase in expression 
was observed in MIDC-LN (Fig.1B). Random forest statistical analysis of NEDD9 staining, which 
achieved an out-of-bag error rate of 0.49, indicates that by using NEDD9 protein levels, one can 
double the predictive power over chance of classifying tumor. The independent prognostic value 
of NEDD9 expression had 70% probability of identifying cases of IDC (Fig.1C).
NEDD9 expression in BCa cells correlates with the capability to degrade ECM. We used a 
panel of characterized human BCa cell lines to determine if NEDD9 expression profiles 
identified in BCa patient samples correlate with invasion potential of cells,. We found that 
NEDD9 protein levels varied across the different cell lines in contrast to the p130Cas/BCAR1 
protein (Fig.1D-E). Several BCa cell lines including MDA-MB-231, ZR-75-1, and BT-549 have 5 
to 8 fold more NEDD9 when compared to the non-transformed MCF10A line. The high NEDD9 
expression levels correlate with the invasive capabilities of these cells (31-32). We confirmed 
these findings using FITC-gelatin degradation assays. Representative images and quantification 
of degradation by MCF7, BT-549 and ZR-75-1 shown in Figure 1F-G and Suppl.Fig.1B. In 
contrast to the highly invasive MDA-MB-231 and BT-549, the AU-565 and MCF7 BCa cells were 
not proficient in gelatin degradation. We and others previously noticed that these cells 
expressed low levels of cortactin (Fig.1D), MMP14, and MMP2 (33) which are required for 
invasion (16). This indicates that NEDD9 is required to support ECM degradation, although 
other components of the invasion machinery are also required for these processes.
NEDD9 localizes to and promotes invadopodia maturation. To define the requirement of 
NEDD9 in formation and function of invadopodia, we infected MDA-MB-231, BT-549, and ZR-
75-1 cells with two different shRNAs targeting NEDD9, which did not effect the expression of 
p130Cas (Fig.2A). Cells were plated on FITC-gelatin coated coverslips and co-stained with 
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invadopodia markers F-actin and cortactin to visualize the area of gelatin degradation and 
pseudopods (Fig.2B-C). Depletion of NEDD9 led to a two- threefold reduction in the number of 
cells degrading matrix, while viability of cells was not affected (Fig.2D). Interestingly, NEDD9 
depleted cells had a similar number of F-actin/cortactin rich puncta (Fig.2E) which are found 
during the initial stages of invadopodia formation (16) but show an absence of degradation 
beneath the puncta (Fig.2C). p130Cas, which is highly expressed in BCa cells (Fig2A), was not 
able to compensate for the decrease in NEDD9 under current experimental settings suggesting 
a critical role of NEDD9 in invadopodia based invasion in BCa. The localization of other major 
components of invadopodia, such as: Arp3 and N-WASP, were not affected by depletion of 
NEDD9 (Suppl.Fig.1C). To determine if NEDD9 localized to invadopodia in BCa cells, we co-
stained cells with anti- NEDD9 antibodies (29) and invadopodia markers (16). We found that 
NEDD9 was consistently co-localized with cortactin, actin, and phTyrosine (Fig.2F-G) in all cells 
with invadopodia.
NEDD9 depletion in BCa cells leads to decrease in 3D invasion. To assess the impact of 
NEDD9 depletion on ECM degradation under more physiological conditions we used matrigel-
DQcollagen I/IV invasion assay to trace invasion and pericellular ECM degradation in 3D matrix. 
BCa cells treated with shRNAs against NEDD9 were deficient in matrix degradation when 
embedded in 3D matrix (Fig.3A-C). The levels of FITC-fluorescence as a result of proteolytical 
cleavage of DQcollagen I/IV were calculated (Fig.3B) in shRNA expressing RFPpositive cells. 
The results were also evaluated in BT-549 and ZR-75-1 cell lines (Suppl.Fig.2AB). shNEDD9 
cells demonstrated severe deficiency in collagen I/IV degradation indicated by a six fold 
decrease in fluorescence. We observed that the area of degradation in control cells had either a 
pericellular or dotted pattern (insert, Fig.3A).
NEDD9 knockdown decreases MMPs activity, but does not affect MMPs expression or 
secretion. MMPs are the key enzymes responsible for matrix degradation. To determine the
potential impact of NEDD9 on the function of MMPs, we analyzed protein levels of MMPs in
shNEDD9 and control cells using a comprehensive MMP antibody array. Serum-free medium
(SFM) conditioned by control and shNEDD9 cells was collected to measure the levels of
secreted MMPs. The whole cell lysates (WCL) were used to define the total protein level of
various expressed MMPs. No significant differences in the total amount of produced or secreted
MMP and tissue specific inhibitor of MMP- TIMPs, were detected (Fig.4A-B), except MMP13
which was slightly elevated in shNEDD9 cells. Nevertheless, analysis of SFM conditioned by
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shNEDD9, but not control, using EnzChek Gelatinase/Collagenase assay shows a severe
deficiency in the activity of secreted collagenases (Fig.4C). Next, we tested the activity of
secreted MMPs by gel zymography. The activity of MMPs, particularly MMP2 and MMP9, was
reduced by 60-80% upon NEDD9 depletion (Fig.4D-E), indicated by the decrease in the amount
of active 68kDa form of MMP2 (Fig.4D, quantification of 68kDa form Fig.4E) and 92-86kDa
forms of MMP9 (Fig.4E). We then tested the activity of MMP14 using a MMP14-specific
fluorogenic substrate and show that NEDD9 depletion results in a significant decrease in
MMP14 activity (Fig.4F).
NEDD9 depletion leads to inactivation of MMP14 by TIMP2. Membrane bound MMP14 is 
one of the key molecules involved in activation of soluble MMPs and pericellular degradation 
(34). Total MMP14 protein level (Fig.5A) and localization patterns (Suppl.Fig.2C) were not 
impacted by NEDD9 depletion. Interestingly, cell surface levels of MMP14 and TIMP2 proteins 
assessed by FACS (Fig.5B-C) and IF (Fig.5D-E) had increased up to 40% upon NEDD9 
depletion. Note, that according to the MMP array analysis performed earlier depletion of NEDD9 
did not affect total expression or secretion of TIMP2 (Fig.4A-B). TIMP2 is a well-known regulator
of MMP14 and MMP2 activity. An increased amount of TIMP2-bound MMP14 is indicative of its 
decreased activity (35-36). Depletion of MMP14 (Fig.6A) and TIMP2 in BCa cells (Fig.6B), using 
specific siRNAs, resulted in a similar to shNEDD9 invasion deficiency (Fig.6C) suggesting that 
MMP14 and TIMP2 are potentially the downstream targets affected by NEDD9. Moreover, 
addition of increasing amounts of recombinant TIMP2 to the medium of control cells leads to a 
similar inhibition of invasion at the higher concentrations of TIMP2 (Fig.6D). Importantly, re-
expression of NEDD9 (Fig.6E) restored the amount of surface-bound MMP14 (Fig.6F) and 
invasion proficiency of shNEDD9 cells (Fig.6G).
NEDD9 depletion inhibits invasion and intravasation of tumor cells from primary site and 
growth of metastasis in xenograft models. To determine the requirements of NEDD9 for
invasion and metastasis in vivo, we utilized human tumor xenografts combined with
bioluminescence imaging (BLI) (27, 30). MDA-MB-231-shCon and shNEDD9 (N1, N4) cells
were injected into the mammary fat pad and allowed to develop primary tumors without
induction of shRNA. When tumor volume reached 150-200mm3 (Fig.7A-shRNA-Day0), animals
were placed on doxycycline-containing food. shRNA expression was monitored by RFP
fluorescence, along with BLI (Fig.7A-shRNA-Day14) and western blotting (Fig.7B). Animals
were euthanized at shRNA Day0 or Day14 which corresponded to 3, and 5 weeks post injection
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of tumor cells to assess for the number of CTCs in the peripheral blood, number and size of
metastases in the lungs and gross pathology of primary tumor. At the shRNA Day0, all animals
had similar primary tumor size and volume based on caliper measurements and BLI 
(Fig.7CshRNA-Day0). Analysis of peripheral blood samples for CTCs reveals similar number in 
all three cohorts of animals (shCon/shN1/shN4) (Fig.7D-shRNA-Day0), as well as similar 
number of metastases seeded in the lungs (Fig.7E-shRNA-Day0). NEDD9 depletion during the 
following 14 days in established primary tumors and metastases led to a drastic decrease in the 
number of CTCs (Fig.7D-shRNA-Day14) and number of metastases in lungs (Fig.7E-F-shRNA-
Day14). The primary tumors had continued to grow during the shRNA induction based on BLI 
data (Fig.7C-shRNA-Day0/Day14); thus, the decrease in the number of CTCs could be either 
due to a decrease in the ability of tumor cells to invade the surrounding matrix and intravasate in 
blood stream or due to decrease in overall survival. We have established that NEDD9 depletion 
did not affect the survival of MDA-MB-231 cells (Fig.7G). Similar results were obtained with 
another metastatic BCa cell line BT-549 supporting the general phenomenon of NEDD9 function 
in invasion and metastasis (Suppl.Fig.3A-D). Collectively, our findings suggest that the 
application of shRNAs against NEDD9 to already established tumors could drastically reduce 
the number of tumor cells released into circulation due to an invasion deficiency, thereby, 
eliminating further seeding and decrease the total number of metastasis.
73 
 
Discussion
While recent studies have established NEDD9 as an essential factor for invasion (2-4) 
and metastasis (1, 37) the precise mechanism of how NEDD9 functions and its contribution to 
various stages of metastasis have been poorly defined. In our current study we show that 
NEDD9 is upregulated in breast tumors, and specifically increases in IDC, giving NEDD9 the 
potential to serve as a strong diagnostic marker for invasive tumors.
Interestingly, NEDD9 is decreased in metastatic samples suggesting that high level of 
NEDD9 is required during the invasion from the primary site, most probably to enable protease-
dependent degradation of the basal membrane and EMT re-programming. While still increased 
compared to normal tissue, lesser amounts of NEDD9 are sufficient during growth at distant 
metastatic sites. Alternatively, upon arrival at distant sites, a decrease in NEDD9 expression 
might be beneficial in order to undergo mesenchymal to epithelial transition to establish the 
colony (8). These data is in accordance with the previously published studies showing that 
established metastasis in lungs had less NEDD9 when compared to primary tumor (6-7, 21-22). 
It is possible that decrease in NEDD9 might be beneficial for migration through filamentous
collagen rich matrices; while in the basal membrane like matrix, the presence of NEDD9 was an 
absolute requirement for efficient invasion.
Decreases in NEDD9 expression, induced by constitutive or inducible shRNAs against 
NEDD9, result in a dramatic decrease in matrix degradation and invasion of BCa cells in 2D, 3D 
environments, and limits number of CTCs and metastases, thus establishing NEDD9 as an 
important factor for invasion and metastasis in BCa. In a search for a molecular mechanisms 
underlying NEDD9 dependent invasion, we found that depletion of NEDD9 does not affect 
formation of nascent invadopodia, characterized by aggregation of F-actin, cortactin, and 
MMP14 (17), but prevents further maturation of invadopodia into proteolytically active structures 
(16). These findings are in agreement with previous report in SCC-9 cells where NEDD9 
expression was required for matrix degradation, but disagree with regard of NEDD9 requirement 
for invadopodia formation (23). The differences might be associated with artificial exogenous 
overexpression of NEDD9 in SCC9 cells. The source of differences could also reside in tissue 
specific behavior of breast versus head and neck cells. It is also needs to be noted that another 
NEDD9 family member protein p130Cas was previously identified in invadopodia (24). In the 
cell lines used in our study depletion of NEDD9 did not affect the formation of invadopodia, 
indicating the different roles of these adaptor proteins in invasion.
The maturation of invadopodia in BCa cells and the capacity of tumor cells to invade 
surrounding tissue are directly linked to accumulation and activation of MMP14 and soluble 
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MMPs (10, 34). We found that depletion of NEDD9 leads to a 60-80% decrease in activity of 
secreted MMP2 and MMP9 and pericellular proteolysis. Activity of MMP14 is tightly regulated by 
TIMP2 which plays dual roles as both inhibitor and activator of MMP14, depending upon 
concentration (35-36). While there is no difference in produced or secreted protein levels of 
MMPs and TIMPs in shNEDD9 and shCon cells, we observed that the concentration of cell 
surface bound TIMP2 and MMP14 is up to 50% higher in shNEDD9 cells, suggesting that the 
decrease in activity of MMP14 and other MMPs is potentially due to an increased amount of 
TIMP2 associated with MMP14 on the cell surface. Interestingly, depletion of MMP14 or TIMP2 
results in a similar decrease in MMP2 activity and invasion deficiency recapitulating the 
shNEDD9 phenotype. TIMP2 is a potent inhibitor of most soluble MMPs (39), thus TIMP2
depletion could also relieve the inhibition of other soluble MMPs produced by cells. 
Nevertheless, our findings indicate that depletion of TIMP2 alone is not sufficient to restore the 
activity of soluble MMPs most likely due to the presence of other TIMPs such as TIMP1, 3 and 4 
(39-40). Re-expression of NEDD9 restores the MMPs activity and invasion proficiency of 
shNEDD9 cells.
Binding of TIMP2 results in increased endocytosis of MMP14 (10, 38) followed by 
dissociation of MMP14/TIMP2 complexes within the endocytic vesicles and regenerate an active 
protease (34). Accumulation of MMP14/TIMP2 complexes on the cell surface is indicative of 
endocytotic deficiency in NEDD9 depleted cells. Interestingly, MMP14 can be phosphorylated 
by Src kinase and this phosphorylation is required for invasion and endocytosis of MMP14 (19), 
thus directly linking the NEDD9 dependent decrease in Src and FAK activity (4, 21) with 
inactivation of MMP14. Further work is required to uncover the intricate link between NEDD9 
and MMP14 trafficking.
The decrease in number of metastases and CTCs upon NEDD9 depletion in cancer cells 
could advocate for development of shRNA based NEDD9-targeted therapy against BCa 
invasion. Importantly, even established, late stage, cancers with seeded metastases based on 
our in vivo inducible xenograft studies might still benefit from shNEDD9 treatment and prevent 
further spreading of disease. Collectively, our findings establish a critical role for NEDD9 as a 
regulator of invasion in BCa through modulation of MMP14 activity, thus delineating a new 
signaling pathway for targeting NEDD9 dependent invasion.
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Figure legends
Figure 1. NEDD9 is overexpressed in invasive breast ductal carcinomas and BCa cell 
lines. (A). Representative images of IHC staining with anti-NEDD9 antibodies in normal breast, 
DCIS, IDC MIDC-LN. (B). Statistical analysis of NEDD9 expression based on intensity of 
staining in (A), mean values +/-S.E.M, one-way ANOVA*, p<0.001 (Normal/IDC, Normal/MIDC 
LN, Normal/DCIS), p<0.05 (DCIS/IDC, IDC/MIDC-LN), ns-non significant (DCIS/MIDC-LN) (C).
The data (B) were analyzed by Random forest statistical software to assess the predictive value
of NEDD9 expression. (D). Western Blot analysis (WB) of NEDD9, p130Cas, cortactin and
tubulin in the indicated cell lines. (E). Quantification of NEDD9 and p130Cas as in (D),
normalized to MCF10A, * p<0.001. (F). Immunofluorescent (IF) staining of MCF7 and BT-549
cells with Rhodamine-Phalloidin (red) and cortactin (green), FITC-gelatin (white). (G).
Quantification of matrix degradation, 100 cells/cell line n=3, % of cells degrading matrix, +/-
S.E.M, * p<0.0001 one-way ANOVA.
Figure 2. NEDD9 localizes to and promotes invadopodia maturation. (A). Top: WB of
NEDD9, p130Cas, actin in MDA-MB-231-shNEDD9 or -shCon cells, Bottom: quantification of
NEDD9 and p130Cas expression normalized to shCon; one-way ANOVA, p<0.001. (B). IF
staining of MDA-MB-231-shCon and -shNEDD9 cells with anti-cortactin (green), -actin (red)
antibodies and FITC-gelatin (blue), scale bar 10 ??????? ? ??? ?? ?? ?
main panel. (C). Enlarged XYZ projections of IF as in (B). (D). Quantification of number of cells 
degrading matrix and F-actin/cortactin positive foci (E) in MDA-MB-231-shCon, - shNEDD9 (N1, 
N4) cells. Student’s t-test for (D): *p<0.001(shCon/shN1, shCon/shN4), ns - shN1/N4; and ns 
(E) +/-S.E.M. (F). IF of MDA-MB-231 cells with cortactin (blue), actin (red) and NEDD9 (green), 
and FITC-gelatin (white). (G). IF staining with anti-phTyr (blue), actin (red) and NEDD9 (green) 
antibodies, and FITC-gelatin (white). Scale bar -??? ?????? ? ??? ?? ?? ?enlarged areas indicated in 
the main panel.
Figure 3. NEDD9 depletion ablates matrix degradation and invasion in 3D matrices. (A).
Representative images of 3D projections live cell imaging of MDA-MB-231-shCon, -shNEDD9
cells embedded in the DQ-CollagenI/IV/matrigel matrix, shRNA (red), DNA (blue) at indicated
time points; xyz projections (z), scale bar -50 ??????? ? ?? ?? ?? ?? ?
rectangle. (B). Quantification of FITC-fluorescence intensity as in (A), % of area degraded per
cell, +/-S.E.M, *p<0.0001 one-way ANOVA. (C). WB of cells in (A-B) with anti-NEDD9 and actin 
antibodies. +Dox indicates the lines used in A-B.
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Figure 4. NEDD9 depletion decreases MMPs activity, but does not affect MMPs 
expression or secretion. (A). WB of total MMPs expressed (WCL) and secreted (SFM) by 
indicated cells, 48h post shRNA expression. Schematic outline the MMP microarray. (B).
Quantification of MMPs and TIMPs expression, n=3, one-way ANOVA for all pairs p is non 
significant; p<0.05 for MMP13 (shCon/shN4). (C). Quantification of gellatinase/collagenese 
activity in SFM conditioned by cells using EnzChek Gellatinase/Collagenese assay. Clostridium 
Collagenase, 0.1U/ml, is positive control, p<0.05 (shCon/shN1 or /N4), linear regression 
analysis. (D). Representative image of -gel zymography, SFM conditioned by MDA-MB-231
shCon, - shNEDD9 cells, WB of MMP2 and MMP9. (E). Quantification MMP2 and MMP9 activity 
as in (D) normalized to total level of MMP2 and MMP9, +/-S.E.M; MMP9: p=0.007 (*) shCon/N1, 
or /N4 and ns - shN1/N4, one-way ANOVA. MMP2: p=0.00031, shCon/N1, /N4, ns -shN1/N4,
one-way ANOVA. (F). MMP14-specific fluorogenic substrate assay, at 328/400mn. Data plotted
as curves described by equation for one site binding kinetics, fitted to each data set with the R2
of 0.8, Extra sum-of-squares F test, p<0.0001.
Figure 5. NEDD9 depletion leads to increase in amount of surface-bound TIMP2 and
MMP14: (A). WB of WCL with anti-NEDD9, -MMP14, -GAPDH antibodies. (B). FACS of
MMP14: surface (non-permeabilized) and total (permeabilized) normalized to shCon; one-way
ANOVA *p<0.005 (shCon/N1 or /N4) -surface cells, ns, -total. (C). FACS of TIMP2-surface,
normalized to shCon; t-test *p=0.039 (shCon/N1), *p=0.0029 (shCon/N4). (D). Representative
images of IF, MDA-MB-231-shCon, -shNEDD9 cells with anti-TIMP2 antibody (red), DNA (blue). 
Scale bar, 20 ??????? ? ??? ?? ?? ?????????????? ??? ??(E). Quantification 
of TIMP2 fluorescence intensity at the membrane as in (D) normalized to shCon; t-test *p<0.001 
(shCon/shN1 or /N4), ns - shN1/shN4.
Figure 6. Inhibition or depletion of MMP14 or TIMP2 recapitulates invasion deficiency of 
shNEDD9 cells. (A-B). WB of WCL of MDA-MB-231-shCon, -shNEDD9 cells treated with 
siCon, siMMP14 or siTIMP2, using anti- NEDD9, -TIMP2 and -a-tubulin antibodies. (C). Boyden 
Chamber invasion assay, cells as in (AB); plotted as relative fluorescence units (RFU), one-way 
ANOVA *p<0.0001 (shCon/siCon, shN1/siCon, or shN4/siCon), ns -shN1/N4-siCon and 
shCon/siMMP14 or shCon/siTIMP2; p<0.005 shCon/siCon, shCon/siMMP14 or shCon/siTIMP2;
(D). Boyden Chamber invasion assay of MDA-MB-231-shCon cells with increased amount of 
TIMP2. MDA-MB-231-shN4 cells used as a reference control. Results plotted as RFU, n=3. 
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One-way ANOVA *p<0.0001 shCon-0nM/shCon-10nM or more, ns: shN4/shCon-10nM. (E). WB 
of NEDD9 rescue in MDAMB- 231-shCon, -shNEDD9 cells with empty vector or cDNA-NEDD9 
construct, using anti- NEDD9,   GAPDH antibodies. (F). FACS of MMP14 surface staining as in 
(E); one-way ANOVA *p<0.0001 empty vector-shCon/shN1 or /N4; ns cDNANEDD9 
shCon/shN1 or /N4). (G). Boyden-Chamber assay, cells as in (E-F). Data plotted as RFU, one 
way ANOVA *p<0.0001 (shCon-empty/shCon-NEDD9, shN1-empty/shN1-NEDD9, shN4 
empty/shN4- NEDD9); p<0.005 (shCon-empty/shN1-empty or -shN4-empty); ns (shCon
NEDD9/shN1- NEDD9 or /shN4-NEDD9). 
Figure 7. NEDD9 depletion inhibits metastasis in xenograft models. (A). Representative
images of bioluminescence and RFP fluorescence of mice orthotopically injected with MDAMB-
231LN-shCon or –shNEDD9 cells. shRNA-Day0-3 weeks post injection, regular chow; shRNA 
Day14-2 weeks doxycycline chow; 6 mice/shRNA/3 independent experiments. (B). WB of 
primary tumor tissue at (shRNA-Day0, -Day14) with anti-NEDD9, -RFP and –actin antibodies.
(C). Quantification of tumor growth based on bioluminescence in 3 independent experiments, 
n=6/group, mean photon flux, +/-S.E.M, one-way ANOVA, p is ns for shRNADay0 (shCon/shN1 
or /N4), shRNA-Day14 (shCon/shN1, shN1/shN4); *p=0.032 for shRNADay14- shCon/shN4. 
(D). Quantification of RFP/luc2/DNA positive tumor cells in peripheral blood of shCon and 
shNEDD9 mice at indicated times, n=6/group/3 independent experiments; plotted as mean 
number of cells per 200 ???????????????-S.E.M, two-way ANOVA, ns (shRNADay0: shCon/shN1 
or /N4); p<0.001 (shRNA-Day14: shCon/shN1 or /N4). (E). Quantification of metastases in lungs 
of orthotopically injected animals at indicated times by pathologist using serial sections of lungs 
and H&E staining, plotted as mean number of metastases per mm2 +/- S.E.M, n=6/group/3 
independent experiments; two-way ANOVA p -ns (shRNA-Day0: shCon/shN1 or /N4); p<0.001 
(shRNA-Day14: shCon/shN1 or /N4). (F). Representative images of H&E staining as in (E). 
Scale bar-500 ?????? ????? ?? ????????-insert. (G). Quantification of number of trypan blue 
negative vs. positive shCon or shNEDD9 cells, 72 in suspension. One- way ANOVA, p=0.0946.
Supplementary Figure 1. (A). Statistical analysis of NEDD9 expression based on intensity and
number of positively stained cells in Fig.1(A) visually determined by two pathologists according
to the scoring procedure described in Material and Methods section. (B). Immunofluorescent 
(IF) staining of ZR-75-1 cells with Rhodamine-Phalloidin (red) and cortactin (green), FITC-
gelatin (pseudo colored white). (C). Immuofluorescent analysis of structural components of 
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invadopodia: Arp3 (green), N-WASP (green), cortactin (red), DNA (blue), FITC-gelatin (white) in 
MDA231- MB-231-shCon, -shNEDD9 (N4) cells.
Supplementary Figure 2. (A). Representative images of live microscopy of BT549-shCon, -
shNEDD9 (N4) cells embedded in DQ-Collagen IV 48h post plating. DNA (blue), shRNA
expressing cells (RFP, red) and degradation of DQ-Collagen (green). (B). Quantification of 
DQCollagen IV degradation as shown in (A). Statistical analysis by one-way ANOVA based on 3
independent experiments in 100-200 cells in each group. *p<0.005 (shCon/shN1 or N4), ns
(shN1/N4). (C). IF analysis of MDA-MB-231-shCon, -shNEDD9 cells with anti-cortactin (blue),
anti-F-????????????????????????????????????????????????????????????? ????????????????????
membrane area with increase in MMP14.
Supplementary Figure 3. (A). Representative images of bioluminescence (BLI) of mice
orthotopically injected with BT-549 cells expressing doxycycline inducible shCon or shNEDD9
(shN1) RNAs. shRNA-Day0 represents 2 weeks post injection, before addition of doxycycline
chow; shRNA-Day14 is 2 weeks post addition of doxycycline-containing diet. 6 mice/each
shRNA (12 mice total). (B). WB (right panel) analysis of primary tumor tissue dissected at
shRNA-Day14 with anti-NEDD9, and -GAPDH antibodies. Quantification of sRNA depletion 2
(left panel) from tumors from 3 mice/per shRNA, t-test *p=0.0019. (C). Quantification of tumor
growth based on BLI (shRNA-Day0, -Day14) in 3 independent experiments, n=6/group, mean
photon flux, +/-S.E.M, two-way ANOVA, p values are non-significant (ns) for shRNA-Day0
(shCon/shN1); *p=0.0007 for shRNA-Day14 (shCon/shN1). (D). Quantification of RFP/luc2/DNA 
positive tumor cells in peripheral blood of shCon and shNEDD9 (N1) mice at indicated time 
points, n=6/group. Results are plotted as number of cells per 20????????????????- S.E.M, two-way 
ANOVA, ns (shRNA-Day0: shCon/shN1); p<0.001 (shRNA-Day14: shCon/shN1).
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Study 3: Generation of a Mammary Specific Nedd9 Knock-in Mouse 
Model
Ryan J. Ice and Elena N. Pugacheva
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Abstract
NEDD9 protein levels are often increased in many types of cancers and are an 
established indicator of poor prognosis. Breast cancer patient samples containing high levels of 
NEDD9 correlate strongly with a more invasive and metastatic phenotype. Additionally, in breast 
cancer cell lines, NEDD9 plays a critical role in the formation of active invadopodia and 
increased migration. In order to investigate the impact of NEDD9 overexpression in vivo, we 
generated a transgenic mouse model with an extra copy of inducible human NEDD9 cDNA 
inserted into the ROSA26 locus on chromosome 6 , which when crossed with any tissue specific 
Cre recombinase expressing mouse strain, will result in overexpression of NEDD9. To assess 
the specific role of NEDD9 overexpression in mammary tumorigenesis and mammary gland 
development, we crossed the founder line with a mouse strain expressing Cre recombinase 
under the control of the mouse mammary tumor virus promoter, MMTV-Cre. The resulting line 
overexpresses NEDD9 protein specifically in the mammary gland epithelial tissue. The MMTV-
Cre-NEDD9+/+ mice were further crossed with the MMTV-Her2 line to mimic oncogene-driven 
tumorigenesis often seen in Her2 overexpressing patients in human breast cancer. The control 
MMTV-Cre, MMTV-Cre/NEDD9+/+ and experimental MMTV-Her2 and MMTV-
Cre/NEDD9+/+/Her2 lines were successfully produced and further studies will be needed to 
examine tumor initiation and progression. The characterization of mammary gland development 
in founder MMTV-Cre- NEDD9 line was completed and  showed a significant increase in the 
branch to bud ratio indicating a possible increase in invasion potential during mammary gland 
development. Taken together the generation of a transgenic mammary gland specific NEDD9 
overexpressing model will aid in uncovering the impact of NEDD9 on tumor initiation and 
progression.  
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Introduction
Invasive breast cancer remains a difficult to treat disease effecting one in eight women 
during their lifetime, often with poor prognosis when metastases are present at the time of 
diagnosis (Siegel 2012, Rugo 2008). Although mutations in tumor suppressor genes such as 
p53 are oncogenic, it is common that increases in signaling not due to mutation are found in 
pro-metastatic and pro-survival signaling proteins such as: Src, FAK, and Akt (Dimri 2007, 
Lahlou 2007, Maroulakou 2007). NEDD9, a scaffolding protein commonly overexpressed in 
various tumor types including breast, is known to enhance the activity of such pathways leading 
to increased invasion, migration, and survival resulting in poor prognosis (Izumchenko 2009).
In order to dissect the role of NEDD9 protein in mammary tumorigenesis in vivo it is 
imperative to define first if overexpression of NEDD9 affects normal mammary epithelium 
function. Additionally, the role of NEDD9 in mammary gland development is an area that has not 
yet been explored. Since NEDD9 has been shown to increase the activity of MMPs and 
degradation in human tumors, and mammary gland bud formation has been shown to be an 
MMP dependent process it would stand to reason that NEDD9 may play a role in mammary 
gland development (McLaughlin 2013, Fata 2004). 
We adopted the strategy of overexpressing human NEDD9 in the mammary gland alone 
instead of the entire mouse since NEDD9 has been reported the play a role in Alzheimer 
disease and necessary cilia functions in the gonads important for fertility (Zhang 2006). To date, 
there are no known tumorigenic mutations of NEDD9, however NEDD9 is commonly 
overexpressed and is known to be involved in tumorigenesis. The importance of NEDD9 in 
mammary tumorigenesis has been illustrated previously by knocking out Nedd9, in the context 
of an oncogene driven spontaneous tumor model system (Izumchenko 2009). Nedd9 knockout
in the context of MMTV-PyVmT and MMTV-neu mouse mammary tumor models showed a 
decrease in the incidence, increased latency , reduced tumor size and reduced number of 
metastasis when compared to original MMTV-PyVmT mice. 
When crossed with MMTV-Her2, Nedd9 knock out animals show a difference of 56% in 
the number of mice that form tumors within one year of age. It should be noted however that the 
Cas family member, p130Cas does have the ability in many instances to compensate for the 
loss of Nedd9. We believe our novel model system more accurately recapitulates patient 
tumors, since patients present with increased levels of NEDD9 protein, and that p130Cas
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compensation is not a factor in overexpression we feel our model to be more clinically relevant 
and possess the ability to test NEDD9 targeted therapies.  
The purpose of this study is to evaluate the role of NEDD9 overexpression in the 
development of mammary gland tumors in the physiologically relevant context. Wild type human 
NEDD9 will be specifically expressed only in the mammary gland epithelia via the MMTV 
promoter. Upon confirmation of specific and significant expression of NEDD9 (recapitulating the 
expression of NEDD9 in human tumors) in mammary epithelium this strain will be crossed with 
a well characterized mouse model of mammary tumorigenesis, MMTV-Her2. The tumor initiation 
and progression in this strain is driven by overexpression of Her2/ErbB2, a growth factor 
receptor of the EGFR family, leading to spontaneous mammary gland tumors and metastasis, 
seen in human cancers characterized by Her2 overexpression.
Materials and Methods
Generation of conditional NEDD9 knock IN (Floxed-STOP-NEDD9) transgenic strain and 
locus insertion.
A targeting vector was utilized for homologous recombination at the Rosa26 locus of the 
murine genome. The insertion portion of the targeting vector contains a CAAG ubiquitously 
expressed promoter (CMV immediate early enhancer/ chicken b-actin promoter fusion), coupled 
to a start site, followed by a stop codon in frame, flanked by LoxP Cre recombinase recognition 
cassettes. Downstream of the LoxP cassette is the coding sequence for NEDD9 (Fig.1A). 
Vector design, mouse embryo injection, and transplantation was performed by GenOway, Inc. 
into a C57BL/6 background. The PCR screening for homologous recombination at the 5’ end of 
the targeting vector was performed using set of designed primers: GX6043/44, generating 
1870kb fragment (Fig.1B). Once chimera mice were generated yielding homozygous floxed 
NEDD9 knock-in offspring, embryos were cryopreserved and stored at the Jackson Laboratory.
Due to the significant impact of genetic background on tumorigenesis the NEDD9 
transgene was transferred to FVB background using speed congenic technology executed by 
Charles Rivers Laboratory and WVU Transgenic Animal Facility. The successful transfer of 
NEDD9 transgene was confirmed by PCR analysis as outlined below. 
Backcrossing strategy
Floxed-STOP-NEDD9 mice were backcrossed from a C57BL/6J background into an 
FVB/J strain background via the selection using MaxBax (Charles Rivers) single nucleotide 
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polymorphism analysis of the offspring. By comparing unique single nucleotide polymorphisms 
possessed by either C57BL/6 or FVB/J we were able to determine which mice to use for further 
breeding in order to achieve the greater than 96% of FVB/J mice background still containing the 
Cre-NEDD9 knock-in allele. The successful transfer was produced after the 3rd crossing (N3) 
with the 98% of transfer to FVB genetic background, resulting in FVB/J-Floxed-STOP-NEDD9.
Similar genotyping protocol as for C57BL/6J was used to confirm the presence of NEDD9 
transgene in FVB/J strain (Fig.2A).
Generation of FVB/J-MMTV-Cre-NEDD9+/+ mice for mammary gland specific upregulation 
of NEDD9.
The FVB/J-Floxed-STOP-NEDD9 mice were crossed with FVB/J-MMTV-Cre mice 
expressing Cre recombinase under the mouse mammary tumor virus (MMTV) promoter, specific 
for mammary gland epithelium. This line was obtained via a gracious gift from Dr. J Michael 
Ruppert. The resultant offspring were genotyped using set of designed primers to detect wild 
type, recombined and Cre-excised allele of NEDD9. Homozygous for NEDD9 insertion FVB/J-
MMTV-Cre/NEDD9+/+ mice were used for analysis of normal mammary gland development and 
for further crosses with mammary tumor models. The upregulation of NEDD9 in mammary 
epithelium was confirmed by western blot analysis (Fig. 2C).
Generation of FVB/J-MMTV-Cre-NEDD9+/+-Her2 mice for mammary gland specific 
upregulation of NEDD9 and Her2/Erbb2/neu oncogene.
FVB/J-MMTV-Cre/NEDD9+/+ mice were crossed with FVB/J-MMTV-Her2/Erbb2/neu mouse 
model for mammary tumors in humans purchased from Jackson Laboratories. This strain 
expresses unactivated wild type cDNA of rat Erbb2. The resultant strain expressing all three 
transgenes: Cre, NEDD9 and Her2 was confirmed by PCR analysis using target specific primers 
as outline in the Genotyping section. This line along with MMTV-Cre, and MMTV-Cre/NEDD9+/+
and MMTV-Her2 are observed for the tumor formation. According to the literature MMTV-Her2 
mice start forming tumors at 8 months or older. We expect that overexpression of NEDD9 will 
promote tumorigenesis by shortening the tumor initiation period, including earlier tumor cell 
invasion and metastasis resulting in a faster growing and more aggressive cancers.
Genotyping
Mouse DNA was isolated from 0.3-0.5cm tail fragment using the PrepEase kit (Affymetrix) as 
per manufactures instructions. Mice were genotyped using the following primers: human 
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NEDD9 knock-in allele= 5’-TCCCAGAGTGTGCCGAGGAA-3’/5’-
GGGCCTTTTGCTGATGAGGG-3’, Rosa26=5’-CAATACCTTTCTGGGAGTTCTCTGC-3’/5’-
CTGCATAAAACCCCAGATGACTACC-3’, Her2=5’-CGGAACCCACATCAGGCC -3’/5’- 
TTTCCTGCAGCAGCCTACGC and Cre= 5’-GGTTCTGATCTGAGCTCTGAGTG-3’/5’-
CATCACTCGTTGCATCGACCG-3’. Using the previously listed primers and PCR Ranger 
mixture (Bioline) resulted in the following band sizes, indication the presence of the allele: 
NEDD9 knock-in= 553 base pairs, Rosa26= 300 base pairs, and Cre= 900 base pairs, Her2= 
600 base pairs (Fig 2A).
Generation of MEFs and knock-in allele test
Mouse embryonic fibroblasts, MEFs, were generated from embryos harvested at day 12 
(E12). Sterile technique was used to avoid cross contamination. Collected embryos were 
minced using #10 scalpel blades and incubated for 15 minutes in 0.25%Trypsiin/EDTA at 37°C. 
Full media, ????????????????????????????????? supplemented with 15% fetal bovine serum 
and antibiotic-antimycotic, was added to neutralize the trypsin. Cells were pelleted by 
centrifugation, re-suspended in full media, plated, and passaged. Cells were cryopreserved for 
later use. 
In order to test the effectiveness of the transgenic construct, inducible NEDD9 knock-in 
MEF cell lines were infected with pre-packaged adenovirus expressing GFP (green fluorescent 
protein), Ad-Cre-GFP (Vector Biolabs) as per manufactures instructions. Infection was 
monitored through fluorescent microscopy and in 24h reached 100% efficacy based on the GFP 
fluorescence when compared to uninfected control. Control and Ad-Cre-GFP infected cells were 
lysed and probed by western for NEDD9 and GAPDH protein levels as previously described (Ice 
2013) (Fig.2B).
Mammary gland resection and analysis
The fourth inguinal mammary gland was resected and prepared as described in (de 
Assis 2010). Briefly, MMTV-Cre recombinase expressing control and MMTV-Cre/NEDD9+/+ 
knock-in virgin female mice were euthanized at 6 weeks of age and mammary glands resected. 
Mammary glands were placed on glass slides and allowed to dry for 10 minutes. Slides were 
then places in Carnoy's fixative (75% Acetic acid, 25% ethanol) for two days. Slides were then 
rinsed in 70% ethanol for one hour, followed by distilled water for 30 minutes. Mammary glands 
were then stained in Carmine Alum stain (0.2% carmine dye, 0.5% aluminum potassium sulfate
in distilled water) for two days. Ethanol washes were then performed for 30 minutes each in 
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increasing concentrations of ethanol (70%, 80%, 95%, 100%). Tissue was then allowed to 
delipidate in xylene for two days followed by mounting. Whole mounts of mammary glands were 
imaged at 4X using an Olympus AZ70 microscope; after which bud to branch ratio was 
calculated in 5 mice per group. Statistical software (Graphpad Prism) was used to determine 
significance via Students T-test with a p-value of 0.0324.
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Results
Experimental rationale and generation of FVB/J-Floxed-STOP-NEDD9 mice
To determine the role of NEDD9 in tumorigenesis and metastasis in vivo, we 
developed a transgenic mouse strain which, when in the presence of Cre recombinase, 
overexpresses NEDD9. Since we do not predict abundant NEDD9 to be oncogenic 
alone, we crossed our strain with the oncogenic strain MMTV-Her2. The generated mice 
containing all three transgenes, Cre, NEDD9, and Her2, will be evaluated for tumor 
latency, burden, size, and metastasis.  An additional advantage of the Cre inducible
model design is the ability to use the multitude of tissue and time specific Cre 
recombinase promoter strains available. 
Evaluation of Cre-dependent expression of NEDD9 in FVB/J-Floxed-STOP-NEDD9
Through utilizing mouse embryo fibroblasts generated from FVB/J-Floxed-STOP-NEDD9 
mice, we were able to overexpress NEDD9 upon infection with adenoviral Cre recombinase. 
Using western blot analysis we detected a robust overexpression of NEDD9 when compared to 
uninfected MEFs (Fig. 2B); therefore, indicating the Cre recombinase inducible vector is 
functional and producing a NEDD9 product of full length which is recognized by monoclonal 
antibody specific to NEDD9. Mammary glands harvested from MMTV-Cre and MMTV-
Cre/NEDD9+/+ indicate that there is indeed an increase in NEDD9 in the mammary fat pad. 
NEDD9 overexpression increases mammary gland budding
In order to evaluate if NEDD9 overexpression effects the normal mammary gland 
development we assessed the difference in mammary gland branching between MMTV-Cre and 
MMTV-Cre/NEDD9 knock-in virgin mice. In order to determine if there is a difference in 
mammary development whole mammary gland mounts were prepared from 6 weeks old virgin 
mice according to the protocols outlined in material and methods section. We found that upon 
NEDD9 overexpression there was an increase in the budding to branch ratio, indicating that 
NEDD9 plays a role in mammary gland development (Fig. 3A-B). Overexpression of NEDD9 
either increases proliferation and/or invasion of normal mammary epithelial cells or could 
potentially predispose to cancer. Further work is needed to validate this phenotype, but it is 
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important to take it into account when analyzing the NEDD9 overexpression impact on the 
background of Her2 oncogene.  The currently ongoing characterization of FVB/J-MMTV-
Cre/NEDD9+/+/Her2 mice will allow us to define the role of NEDD9 in mammary tumorigenesis. 
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Discussion
Cre recombinase inducible transgenic mouse model systems provide a versatile tool for 
the study of protein in either a tissue or time specific manner. By developing a Cre inducible 
human NEDD9 knock-in mouse model system we are able to study the role of overexpressed 
NEDD9 in a mammary specific context similar to what is present in breast cancer patient 
samples. 
The previous studies have investigated the role of NEDD9 in mammary tumorigenesis 
(Izumchenko 2009, Little 2012) using NEDD9 knockout mouse model crossed with  mammary 
specific oncogenic mouse strains, MMTV-PyVmT and MMTV-Her2. While both studies did show 
that NEDD9 plays a role in tumor growth, latency, and burden. A major complication of this 
strategy is the ability of p130Cas, a protein in the same family as NEDD9, to be induced and 
compensate for loss of NEDD9. In this instance the importance of NEDD9 in tumorigenesis 
would be difficult to accurately evaluate understate.  It is for this reason that we believe our 
developed model system more accurately portrays native mammary tumorigenesis.
Both NEDD9 and Her2 are found to be overexpressed in breast cancer, and therefore 
make a more clinically relevant model system to study tumorigenesis. By creating this model 
system we will be able to study novel anti-metastatic therapies, since NEDD9 has been shown 
to be a marker of metastatic disease. Additionally, the inducible nature of our model provides 
versatility through crossing it with other tissue and time specific Cre promoter driven mouse 
strains. Finally, our model can be helpful for future drug development targeting NEDD9 and 
NEDD9-dependent signaling pathways. 
Taken together our results illustrate the creation and application of a Cre recombinase 
inducible NEDD9 knock-in mouse model. Additionally, we were able to establish using our novel 
model system that overexpressing NEDD9 in mouse mammary glands increases mammary 
gland development, which could be attributed to the role of NEDD9 in increasing MMP activity
during tumorigenesis (McLaughlin 2013), although more studies need to be performed to prove 
this point directly.  
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FIGURES: 
A
B
Figure 1. Design and expression of Cre inducible nedd9 knock-in. A) Design of Cre 
recombinase inducible NEDD9 knock-in vector for homologous recombination at the Rosa26 
locus (top). In the presence of Cre recombinase the STOP cassette is resected out of the 
genome due to flanking LoxP sites (middle) resulting in CAAG promoter driven NEDD9 
expression (bottom) B) PCR test using GX primer set for homologous recombination. 
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A
B                    MEFS             C
Figure 2. A )Genotyping results in triplicate indicating the presence of either the Rosa26 loci 
or the NEDD9 loci. B) Western blot analysis of lysates of mouse embryo fibroblasts 
prepared from nedd9 knock-in mice with and without being infected with adenoviral Cre 
recombinase. NEDD9 protein levels are greatly increased and producing full length 
transcript upon infection. C) Western blot analysis of mammary tissue taken from Cre-Nedd9 
and Cre-WT mice. Levels of NEDD9 protein are increased in the Cre positive mouse.
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A
B
Figure 3. NEDD9 overexpression results in increased budding of mammary glands.
A) Top, a representative image taken of a whole mount section of the fourth inguinal 
mammary gland of a 6 week old virgin Cre/NEDD9 knock-in mouse. Bottom, a closer view of 
a mammary tree. Arrows indicate a bud, branch, and terminal end bud. B) Quantitation of 
bud to branch ratio indicating a significant increase in mammary gland development upon 
NEDD9 overexpression. The n=5 with a p-value of 0. 0324.
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Study 4: Development of breast cancer patient derived xenograft 
mouse model for the testing of AURKA inhibitor sensitivity and 
biomarkers.
Ryan Ice and Elena Pugacheva
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Abstract
The ability to mimic tumor development and metastasis in mouse models in vivo is 
critical for the development of novel targeted therapies. Unfortunately, genetically engineered 
mouse models (GEMs) which produce tumors through the induction of a single oncogene or 
elimination of a single tumor suppressor are rarely seen in the human population. Most tumors 
are produced through sequential induction/mutation or elimination of multiple genes and 
selection through the prolonged period of time. Additionally, models for hormone related 
cancers, such as breast and prostate cancer, do not recapitulate the human tumor due to 
differences in hormone production/regulation cycles between mouse and human physiology. 
Cell line derived xenograft mouse models are also fraught with obstacles, such as: 
homogeneity, aberrant mutations due to being grown in culture, and lack of tumor 
microenvironment. Often cell line derived xenografts fail to recapitulate patient-specific pattern 
of metastatic spread. Due to these limitations, patient derived xenografts have been developed 
and are becoming a widely used tool for cancer therapeutic research. In our study we establish 
the patient derived breast cancer xenografts (PDBCX).  These will be later used to define the
efficacy of AURKA inhibitor (alisertib-MLN8237) in the treatment/or prevention of metastasis to 
the local and distant organs and could be used to assess tumor susceptibility and identify 
biomarkers of drug response to streamline the eradication of metastases.
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Introduction
Breast cancer remains the most common non-skin cancer among women and is 
considered the second leading cause of cancer related mortality in women. The vast majority of 
deaths are caused by metastatic disease. Despite significant progress in treatment options, a 
cure of metastatic breast cancer remains elusive. Therefore, it is clear that novel treatment 
strategies are required to be developed. A focus on invasion and metastasis is important since 
as breast cancer advances from regional to metastatic disease survival rates drop from 82 
percent to 26 percent (Siegel 2012).  Unfortunately, the translation from cancer cell biology to 
clinical application has been fraught with peril. One study suggests that as many as 90 percent 
of new cancer drugs fail in the clinic (Hait 2010). One such reason for the low rate of success is 
the lack of accurate in vivo models of breast cancer. Current models utilize cell lines which have 
been selected for proliferation and for the ability to grow on non-physiological surfaces, such as 
plastic. Moreover, when breast cancer cell lines are utilized for xenograft injections the tumor 
microenvironment does not recapitulate the endogenous tumor microenvironment. The 
influence of the tumor microenvironment has become understood and is necessary for accurate 
models for inhibitor testing. Under these circumstances, it is understandable that data generated 
using such tools may not be directly translatable to clinical applications (Clarke 2009, 
Voskoglou-Nomikos 2003). 
By developing the ability to engraft tumor tissue taken from patients and engraft 
orthotopically into immunocompromised mice we are able to retain both the tumor 
heterogeneousness and the surrounding tumor microenvironment of the original tumor. 
Previous studies have shown that through the use of patient derived xenograft transplantation 
one can more accurately predict the response of patients to various inhibitors, allowing for 
multiple treatment regiments to be tested simultaneously (DeRose 2011). Additionally, patient 
derived xenografts are able to phenocopy the location of metastasis presented by patients, 
while cell line generated tumors do not, illustrating there utility in studying inhibitors that target 
metastasis (Press 2008, Carey 2010, Daniel 2009). 
Aurora kinase A (AURKA) is a serine/threonine kinase which plays a key role in the 
G2/M transition of mitotic cells. AURKA is essential for normal mitotic spindle formation, 
centrosome maturation, and subsequent separation. Many cancer types, including breast, were 
found to have high levels of AURKA.
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AURKA inhibitors have recently entered Phase III clinical trials for cancer treatment with 
favorable pharmacodynamics and pharmacokinetics, and limited toxicities in hematological 
cancers. Unfortunately, the average benefit derived from AURKA inhibitors in advanced solid 
tumors has been disease stabilization with few documented instances of tumor regression 
(Siegel 2012, Hait 2012, Clarke 2009, Voskoglou-Nomikos 2003, DeRose 2011, Press 2008).
Our understanding of the molecular factors influencing sensitivity and resistance to AURKA 
inhibitors remains limited. AURKA expression is directly linked to advanced tumor stage and the 
occurrence of metastasis (Voskoglou-Nomikos 2003). Interestingly, it was noted that the 
disease relapse and the metastatic dissemination was lower in those patients treated with 
AURKA inhibitors (alisertib). There is a critical need to determine the efficacy of AURKA 
inhibitors in the prevention and/or treatment of metastasis using more physiologically relevant 
modes such as patient-derived metastatic tumor xenografts (DeRose 2011).  Identification of a
spectra of cancers sensitive to AURKA inhibitors will provide new diagnostic tools to select 
patients who will most likely benefit from AURKA inhibitors and new therapies to treat 
metastasis. Completion of these studies is expected to provide new critical knowledge regarding 
usage of AURKA inhibitors in the treatment of late stage, high risk of metastasis patients. 
In our previous study we found the inhibitor MLN8237 (alsertib) is able to inhibit 
metastasis in cell line derived orthotopic xenografts and that reducing the levels of NEDD9 
enhanced the anti-metastatic effect of MLN8237 (Ice 2013). The goal of this study is to establish 
the patient derived breast cancer xenografts (PDBCX) model system and tissue bank to be 
used for the future purpose of evaluating the efficacy of anti-metastasis therapies.
Materials and Methods
Patient sample selection for transplantation into mice. The following clinical characteristics 
of the patients will be considered at the procurement stage: large tumor size (20>mm), and 
stage III and IV with local/distant metastasis confirmed. Samples were either acquired from the 
lab of Dr. Alana Welm at the Huntsman Cancer Institute at the Univeristy of Utah or through the 
Cooperative Human Tissue Network at the National Cancer Institute.  The number of samples 
for this study is based on published records and tumor uptake rates. We have collect 13 
biopsies for stages III-IV (Table 1). Engraftment of late-stage tumors (stage III-IV) is 40-60% 
(DeRose 2011). The NSG mouse strain has demonstrated up to 100% tumor retention and is 
considered the best model for human cancer transplantation (Ishikawa 2005). Based on this 
evidence we expect at least 60% of collected breast cancer biopsies will be successfully grafted 
in NSG mice. We have currently six  tumors successfully engrafted.
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Patient Tumor collection and processing
Upon resection, tissue samples were collected and submerged in Dulbecco's Modified Eagle 
Medium, (DMEM, Sigma) and stored at 4°C on ice during shipment. Tissue samples were 
processed within 24 hours of collection. Upon arrival, samples were divided into approximately 
2mm cubed pieces. 
Portions of tissue were fixed in Zn based formalin fixative (Fischer Scientific) and 
embedded in paraffin for later analysis of stroma profile and immunohistochemical staining. 
Portions of the tissue were flash frozen in liquid nitrogen for analysis by western blot using anti-
NEDD9 2G9, anti-AURKA (Becton Dickinson), and anti-AURKA Thr288 (Cell Signaling) as 
previously described (Ice 2013). Remaining tissue specimen pieces were either immediately 
transplanted or cryopreserved in 95%serum, 5% dimethyl sulfoxide (Sigma) and stored in liquid 
nitrogen. 
Engraftment of the Tumor Biopsies in NSG Mice. Breast cancer fragments are obtained from 
patients at the time of surgery or biopsy (before neo adjuvant treatment) and grafted into the fat 
pad of 4-6 weeks old female NSG mice. Mice are maintained in BSL2, pathogen-free animal 
housing at the WVU Animal Facility. Based on our experience, tumors start growing at the graft 
site between 2 to 8 weeks after surgery. Each patient derived tumor, upon successful growth in 
the mouse, will be isolated and the tumor mass cut into 1x2x2mm (WxHxL) fragments and 
transplanted into the mammary fat pad of a new NSG mouse. This procedure is called 
passaging of tumor and could be repeated up to 10-15 times to expand the number of animals 
bearing the tumor of the same origin. Finally, a portion of the tissue is stored frozen in DMSO-
fetal bovine serum, freeze-dried in nitrogen for use in further studies, or fixed in PBS/10% 
formalin for histopathological analysis. 
Histology of xenografts and comparison with original patient tumors. The comparison 
between the histology of the original tumors and their xenografts will be established at early and 
later passages by a pathologist at WVU’s Pathology Core Facility (Dr. Livengood) using 
paraffin-embedded sections and standard imunohistochemistry (IHC) staining protocols, which 
are currently under preparation. The histology of the original tumor is usually conserved in 
xenografts (DeRose 2011). The morphology of cancer cells and the stroma will be assessed in 
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original tumors and in xenografted biopsies by IHC staining with specific epithelial and cell 
proliferation markers to confirm the stable propagation of tumor.
Tumor and Estrogen implantation 
De-identified tumor tissue samples were obtained under HIPAA guidelines with informed 
consent. All procedures and protocols were approved by WVU IACUC and veterinary staff. The 
surgical procedure of tumor transplantation and preparation was performed as described in 
DeRose et al. (DeRose 2011).  Transplantation of tumor tissue was performed using aseptic 
technique under sterile conditions. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient 
mice (Jackson Laboratory, stock 5557) were anesthetized using isoflurane/oxygen mixture 
between 2-0.5%. Prior to surgery bupivacaine and carprofen were administered subcutaneously 
for local and general analgesic pain relief respectively.  The fourth inguinal mammary gland of 
female mice 4 to 6 weeks of age was resected thus removing the mammary tree. Tumor tissue 
was inserted in the location of the fourth inguinal mammary gland. An incision was then made 
between the scapulae, where an estrogen supplement pellet was placed. 7mm wound clips 
were used to close both incision sites. Carprofen was administered once daily for three days. 
Mice were monitored for seven days post-surgery until wound clips were removed. 
Ultrasound analysis of Tumor growth and angiogenesis.
Following tumor transplantation, tumor size and blood flow was measured via the 
Vevo2100 Micro-Ultrasound System. A 40 or 50 mHz transducer was used and a 3-dimensional 
image (3D) was acquired with 0.051 mm between images. Blood flow was assessed as the 
Doppler signal within the tumor. Using the integrated software, the images were reconstructed 
to create a 3D image of the tumor at various time points. Upon establishment of growth rate and 
engraftment success, tumors were resected, banked, and cryopreserved for later experiments.
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Results
The rates of successful engraftment of breast cancer tissue 
The collected tumor tissue from a patient biopsies and surgical resections were
transplanted into NSG mice. The following categories are currently present in our collection ER 
positive, Her2 positive, and triple negative (Table 1).To date we have been able to successfully 
grow the following transplanted tumors (PEN_001, PEN_002, PEN_003, PEN_006) which is 
30% of engraftment. All successful grafts so far are invasive ductal carcinomas (IDC).The 
following tumors were not able to grow PEN_004, PEN_005, even though other labs have 
successfully achieved engraftment from these samples after prolonged growth period. 
Differences in engraftment rates could be due to others using mesenchymal stem cells to 
increase angiogenesis. Also we noticed that tumors from patient undergone neo-adjuvant 
chemotherapy had much slower growth rates and were not successfully grafted during 8 weeks 
period. To date, no indicator has been established as a marker for engraftment.
Analysis of engrafted tumor growth and passaging.
Tumor volume and growth was monitored using VEVO ultrasound (Figure 1). 
Transplanted tumor samples were able to re-establish blood flood and induce angiogenesis as 
seen by Doppler ultrasound. Engraftment was achieved in various tumor types including 
estrogen receptor positive tumors, which need to be supplemented with estrogen in the form of 
slow release estrogen implanted subcutaneously. We have collected so far four tumors that 
have successfully engrafted.
Discussion
Even though cell line derived tumor xenografts are of great usefulness due to the easy of 
manipulating protein expression and infection with viral vectors, the main caveat of cell line 
derived model systems is that they do not accurately replicate a spontaneous tumor. The lack of 
heterogeneity and stroma dynamics, together with the fact that cell lines have undergone 
selection for fast division and the ability to grow on tissue culture dishes, is a source for 
divergence of response between patients and cell line model systems. By utilizing patient tumor 
xenografts, which have never been grown in tissue culture, we are able to better replicate the 
tumor of a patient. Only by recapitulating the tumor of a patient can xenograft inhibitor studies 
accurately predict the response of a patient to therapy. 
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Since patient tissue is human and present with foreign antigens immunocompromised
mice must be used in order to avoid rejection of the patient tumor tissue. One hurdle patient 
derived xenograft systems still need to overcome is the lack of immune system contribution, 
which growing evidence shows is a major contributor for tumor development and metastasis,
such as tumor associated T cells and macrophages; though this can be overcome through 
humanization of the immune system of the transplant mouse (Motz 2013).
Despite lacking an immune system to aid in development and metastasis, by utilizing our 
developed patient tumor xenograft bank we will be able to probe for markers indicating 
metastatic location, growth, and AURKA inhibitor susceptibility. Additionally, we will be able to 
gather tumors that metastasize to various locations to test whether AURKA inhibitors can be 
used to treat specific sites of metastasis or metastasis in general. Perhaps of even greater 
impact is that once gathered, our tumor tissue library can be a resource for future inhibitor 
studies once new technologies and inhibitors are developed without the need to recruit patients 
for clinical trials. 
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Figures:
Figure 1. Successful engraftment of patient derived xenograft tumor. A
Composite of VEVO Ultrasound images taken at four weeks post-surgery of 
PEN_003 engraftment. Tumor volume equaled 60.63mm3.
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Table 1. Patient Derived Xenograft Tumor Tissue Received.
Table abbreviations: NAT, normal adjacent to tumor; MAL, malignant; IDC, invasive ductal 
carcinoma; Chemo, chemotherapy; F, female
PDX_ID PDX ID (original)
NAT/
MAL Diagnosis Source Sex Age Race
Treat
ment
ER/PR
/Her2
PEN_001 M1131301A9 MAL IDC Ohio St F 81 W +/-/-
PEN_002 HCI_001 MAL IDC Utah F N/A N/A None -/-/-
PEN_003 HCI_002 MAL IDC Utah F N/A N/A None -/-/-
PEN_004 HCI_009 MAL adeno-carcinoma Utah F N/A N/A Chemo -/-/-
PEN_005 HCI_010 MAL IDC Utah F N/A N/A Chemo -/-/-
PEN_006 M1132001A1 MAL IDC Ohio St F 56 W -/+/-
PEN_010 M1132321A2 MAL papillary carcinoma Ohio St F 67 W
PEN_012 ED63092T_003 MAL IDC UPenn F 35 W Chemo
PEN_014 ED63407T_003 MAL carcinoma UPenn F 58 B Chemo
PEN_016 ED63423T_004 MAL IDC UPenn F 32 W None
PEN_018 ED63703T_004 MAL IDC UPenn F 49 W None
PEN_020 ED62917_T003 MAL carcinoma UPenn F 64 W None
PEN_021 M1132517A2 MAL IDC Ohio St F 61 W
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General Discussion
Collectively, the studies executed in the course of this dissertation work present 
multiple novel insights pertaining to the role of NEDD9 in tumorigenesis, metastasis, 
and cancer treatment. In Study 1, we demonstrated that NEDD9 protects AURKA from 
degradation through blocking CDH1 binding and therefore increasing the amount of 
AURKA present in the tumor cell. We were also able to establish that in patient samples 
the levels of AURKA and NEDD9 are correlative, indicating that the phenomenon is 
present in patient tumors. Additionally, we discovered the major finding that the AURKA 
inhibitor MLN8237 (Alisertib) greatly reduced metastasis via two different complimentary 
methodologies and that by reducing the levels of NEDD9 we were able to sensitize the 
tumor cells thereby virtually eliminating all signs of metastasis. Although the precise 
mechanism of action is an area that will need further investigation, these results indicate 
a clear clinical use for AURKA inhibitors in treating metastatic disease and the use of 
NEDD9 as a biomarker for AURKA inhibitor susceptibility.
Furthermore, the ability of NEDD9 to increase invasion and metastasis in breast 
cancer through regulating TIMP2 and therefore MMP14 in Study 2 provides a novel 
mechanism for NEDD9 dependent invasion and migration. Although, previous studies 
have found NEDD9 to increase invasion and migration via increasing Src and FAK 
activity (Law 1996), the addition of yet another mechanism points to the fact that siRNA 
based therapies need to be developed to target NEDD9. 
In order to investigate the effects of NEDD9 overexpression in the context of in 
vivo tumorigenesis we developed a novel inducible mouse line in Study 3. Through our 
developing of a Cre recombinase inducible NEDD9 knock-in mouse line, we were able 
to investigate the role of NEDD9 in mammary gland development. Illustrating that, 
overexpression of NEDD9 leads to an increase in mammary gland bud to branch ratio 
indicating enhanced development. Interestingly, mammary gland development has been 
shown to be a MMP dependent process, and while it will take more investigation to 
prove that the ability of NEDD9 to regulate MMP activity in vivo is indeed the 
mechanism of action, it is a promising area for research. 
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Lastly, in our striving to better recapitulate human breast cancer we have
developed the capability to utilize the novel method of patient derived xenografts. By 
creating a tissue bank of human tissue samples and cataloging tumors which engrafted 
we will have an inexhaustible supply of human tissue and at the same time be able to 
treat the tumor of a patient with therapies that are not even developed yet. More to our 
purpose, we will be able to test the ability of the AURKA inhibitor MLN8237 to treat 
metastatic breast cancers which phenocopy the metastatic sites present in patients. 
Additionally, we will be able to find biomarkers indicating susceptibility to AURKA 
inhibitors without the need of a full clinical trial. Although the influence of an immune 
system is a hurdle that needs to be overcome, the development of the patient derived 
xenograft system we will be able to more quickly weed out therapies that are ineffective 
in human disease, and thusly be able to progress with greater success in clinical trials.
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